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ABSTRACT 
 
 
Hepatitis B virus (HBV) and human immunodeficiency virus (Thakur et al.) are endemic in 
South Africa. There no data on the HBV genotypes prevailing in HIV-infected South 
Africans.  The aim this study was to determine the HBV genotypes in HIV-infected patients 
and to identify mutations occurring in the basic core promoter/preccore (BCP/PC) and 
complete S regions. Twenty six HBV isolates from HBV-HIV co-infected individuals from 
Helen Joseph urban hospital prior to and at six month after initiation of HAART were 
analyzed. Three hundred HBV isolates from the rural Shongwe Hospital were recruited prior 
to treatment. Restriction fragment length polymorphism (RFLP) together with sequencing of 
the  BCP/PC and complete surface region amplicons were employed for genotyping and 
analysis. There was no significant difference in the HBV genotypes from both cohorts.  
Subgenotype A1 was the predominant genotype.  HBV DNA was detected in 13/26 (50 %) 
Helen Joseph patients and  72/300 (24%) HBV DNA was detected in patients from Shongwe 
cohort: 28/300 (9.3%) HBsAg-positive and 44/300 (14.7%) HBsAg-negative. The BCP/PC 
region of HBV isolates from both cohorts showed mutations that could account for the 
HBeAg negativity, although in the case of the Helen Joseph cohort the HBeAg status was 
unknown because of depletion of serum.  The HBeAg negativity in 44/49 Shongwe patients 
(89,7%) could be accounted for by the following mutations: 1) the basic core promoter 
mutations T1753C A1762T G1764A, which down regulate transcription of precore mRNA; 
2) the Kozak sequence mutants that affect HBeAg translation, 3) the G1862T mutation, 
which interferes with post-translational modification of the HBeAg-precursor, and 4)  the   
classical G1896A stop codon mutation with C1858T. The G1862T mutation occurred in 
HBV from 24.1% HBsAg-positive Shongwe patients but in none of the HBsAg-negative 
patients (p<0.05). PreS deletion mutants were found in isolates from both cohorts.  These 
have previously been described in hepatocellular carcinoma patients. The Helen Joseph HBV 
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isolates had the “a” determinant and immune/vaccine escape mutants. In addition to these, 
Shongwe isolates had HBV reactivation markers mutations V168A + S174N in 23.8% of the 
HBsAg-negative and in none of the HBsAg-positive infections. Drug resistant mutations 
were found in three Shongwe HBV isolates from ART naïve individuals and in none Helen 
Joseph HBV isolates. In conclusion, South African HIV-infected individuals were 
predominantly infected with subgenotype A1 of HBV.  Mutations in the BCP and precore 
region of HBV isolates could account for the HBeAg negativity in the majority of patients.  A 
number of HBV isolates displayed  both immune escape and drug resistance mutations that 
were responsible of the HBsAg-negativity in patients from which they were isolated.   
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CHAPTER 1:  INTRODUCTION 
 
Hepatitis B virus (HBV), with a genome of 3 200 base pairs, is the smallest DNA virus 
infecting  man, yet it is one of the most important human pathogens, causing major health 
problems globally. HBV is endemic in several parts of the world (Alter, 2003, Hou et al., 
2005) and causes chronic and acute infections associated with severe liver diseases, including 
hepatitis, cirrhosis, hepatic fibrosis and  hepatocellular carcinoma  (HCC) (Mahoney, 1999, 
Quarleri et al., 2007) (Salisse and Sureau, 2009) Although there  is a safe and effective 
vaccine against HBV and great progress has been made in the treatment of the infection 
(Francois, 2008),  an estimated 380 million people in the world are chronically infected with 
the virus (Soriano et al., 2008). 
 
Thirty four  million people globally are infected with the human immunodeficiency virus 
(Thakur et al., 2002). As a result of shared blood-borne transmission routes such a s sexual 
and injection drug use (IDU) (Shire et al., 2007), HBV  and  HIV have been shown to cause 
major public health problems in the world.  An estimated four million people worldwide are 
coinfected with HBV-HIV (Burnett et al., 2005).  Moreover, the prevalence of the HBV-HIV 
co-infection is very high in Africa especially in e Sub-Saharan Africa, where both viruses are 
endemic (Selabe et al., 2007, Soriano et al., 2008, Thio, 2003).   HIV  infection leads to the 
acquired immunodeficiency syndrome, opportunistic infections and premature death 
(UNAIDS, 2009, Hazenberg et al., 2003).  Under certain conditions, HIV can have  serious 
and  harmful effects on the clinical outcomes of hepatitis B (Nunez et al., 2006).  
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1.1 THE HEPATITIS B VIRUS  
 
1.1.1 Classification  
HBV belongs to the family of enveloped DNA viruses, the Hepadnaviridae, which consists 
of two genera: the Orthohepadnavirus, infecting mammals and Avihepadnavirus, infecting 
birds (Seeger and Mason, 2000). All hepadnaviruses share a similar structural and genomic 
organization containing a partially double-stranded DNA genome. They all replicate via an 
RNA intermediate, the pregenome, which encodes an error-prone polymerase enzyme with 
both DNA polymerase and reverse transcriptase activity (Nassal and Schaller, 1993, 
MacDonald et al., 2000b) and the capsid protein (HBcAg).  Human HBV is the prototype 
member of the family Hepadnaviridae and has a narrow host range, infecting  humans and 
chimpanzees only (Lai, 2002). The  other members of the family  include the chimpanzee 
hepatitis virus B (ChHBV) (Hadler et al.), woolly monkey hepatitis B virus (WMHBV) 
(MacDonald et al., 2000a), gibbon hepatitis B virus (GiHBV) , orang-utan hepatitis virus 
(OuHV), woodchuck hepatitis virus (WHV) and ground squirrel hepatitis B (GSHV) 
(Scaglioni et al., 1996).  
 
1.1.2 Transmission 
 
HBV, like HIV,  is transmitted through percutaneous and mucous membrane exposure to 
infectious blood and other body fluids that contain blood (Alter, 2003). Modes of 
transmission include sexual, perinatal, and parental/percutaneous transmission (Hou et al., 
2005). Percutaneous HBV transmission includes injection drug use, transfusions and dialysis, 
acupuncture, working in a health-care setting, tattooing, circumcision and scarification, and 
household contact. Although HBV surface antigen (HBsAg) has been detected in variety of 
body fluids besides blood, including saliva, sweat, semen, breast milk, urine and faeces, only 
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blood serum, semen and saliva have been shown to transmit the virus efficiently (Bancroft et 
al., 1977, Gray et al., 1989). Sexual transmission of HBV occurs in all areas of the world; 
however it is more common in areas of low HBV endemicity such as North America, with 
homosexual men being considered to be at the highest risk (Alter, 2003).  
 
The horizontal mode of transmission is the most common route in Africa, whereas perinatal 
route is very common in the far east countries, including China, and Japan (Hou et al., 2005).  
In Africa, transmission occurs predominantly in early childhood, by horizontal transmission 
of the virus via contact with siblings and unrelated playmates as well as other family 
members (Kew, 1996).  
 
1.1.3 Epidemiology   
 
As a result of different socioeconomic conditions, the proportion of the population with risky 
lifestyles, the current prevalence of HBV, the availability of vaccination programs and 
compliance to hygienic measures and transmission routes, HBV infection occurs at markedly 
different prevalence rates geographically. As measured by the presence of HBsAg, the world 
can be divided into areas of  low (<2%), intermediate (2-8%) and high (>8) endemicity (Hou 
et al., 2005).  
 
In Africa very high endemicity of HBV is seen in developing regions with large populations 
and most infections in these highly endemic areas occur during infancy or early childhood. 
More than 8 % of the population in these areas is chronically infected with HBV and 70-95 % 
of the population bears serological evidence of past or present HBV infection. Sub-Saharan 
Africa, most of the  West, East, Central and sub-Saharan Africa with chronic infection rates 
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of 7-26%, nonetheless areas like Kenya, Cote d’Ivoire, Liberia, Sierra Leone, Senegal and 
Zambia are moderately affected with intermediate endimicity rates between 2 and 8 %  
(Kramvis and Kew, 2007a), this  shows mixed patterns of transmission, including  infant, 
early childhood and adult transmission (Hou et al., 2005, André, 2000). Low endemicity is 
found in  the northern African countries of Egypt, Tunisia, Algeria and Morocco  with 
prevalence rates of less than 2 % (Figure 1.1) (Kramvis and Kew, 2007a). 
 
 
 
Figure 1.1: Geographic distribution of chronic HBV infection showing the high, intermediate 
and low prevalence areas in Africa (Kramvis and Kew, 2007a). Reproduced with permission 
from Prof. A. Kramvis. 
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Sub Saharan Africa remains the region most heavily affected by HIV.  In 2008, sub-Saharan 
Africa accounted for 67% of the world’s HIV infections, with Swaziland, South Africa, 
Lesotho, and Botswana being the African countries with the highest rates of HIV infection 
(Fix et al., 2007, Selabe et al., 2007). Of the 34 million people infected with HIV, an 
estimated 2-4 million are chronically infected with HBV.  
 
The prevalence of HBV in HIV-infected individuals varies with the population studied. 
Several non-African studies support an increased prevalence of HBV in HIV-infected 
populations of sub-Saharan Africa with more than 80% of HIV-positive individuals in some 
of the countries carrying serum markers for HBV. African studies have found no increased 
prevalence of exposure to HBV in HIV-positive individuals, but have still raised questions 
about the impact that HIV may be having on the epidemiology of HBV. (Burnett et al., 2005, 
Selabe et al., 2007).  
 
1.1.4 HBV Biology and viral structure 
 
The Dane particle or complete virion of  HBV has a diameter of 42- 47 nm and consists of a 
spherical outer shell, comprising of envelope proteins and a small amount of lipid, and an 
inner nucleocapsid enclosing the  genome (figure 1.2) (Seeger and Mason, 2000, Locarnini et 
al., 2003). The envelope is composed of the large (LHBs), the middle (MHBs) and the small 
(SHBs) surface proteins (figure 1.3 B). The inner icosahedral nucleocapsid encloses a 
partially double stranded relaxed circular DNA particle, which is covalently bound to the 
viral polymerase (Kann, 2002).  The negative strand of the HBV genome is approximately 
3.2 kb in length and consists of four overlapping open reading frames and cis-acting elements 
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required for regulating HBV gene expression and replication(Su and Yee, 1992)  The positive 
strand, which varies in length maintains the circular structure of the genome by cohesively 
binding to the 5’ and 3’ ends of the negative strand (Mahoney, 1999). 
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Figure 1.2 The hepatitis B virion structure (Dane particle) consisting of the small, middle 
and large glycosylated surface proteins as well as the lipid bilayer; the core; the polymerase 
protein; the enzymatic proteins and the partially double stranded DNA genome. (Kann, 2002). 
Reproduced with permission of International Medical Press, © 2008 
 
 
Figure 1.3 HBV virions and subviral particles structure:  (A) An electron micrograph 
(x210,000) of hepatitis B virus in serum indicating the three distinct subviral particles; (1)  
represents the small empty spherical particles, (2) represent infectious virions (Dane particle) 
and (3)  represent the filamentous particles  (Zentgraf, 2002). (B): schematic drawing of the 
20 nm  sphere and filament virion particles  (Kann, 2002). Reproduced with permission of 
International Medical Press, © 2008. 
 
In the serum of HBV infected individuals, two different subviral particles can be found: the 
spherical 20 nm particles and the filamentous particles, which vary in length (figure 1.3A). 
The spherical and filamentous particles consist of viral surface proteins and host-derived lipid 
components (Kann, 2002), different from the complete Dane particle, these subviral particles 
lack nucleic acids and therefore are non-infectious. During infection, the subviral particles 
constitute over 90 % of the total HBV particles with titres ranging from between 106 and 1014 
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particles per millimetre of infected serum (Scaglioni et al., 1996). The reason for the 
occurrence of these particles in higher titres is unknown, however, it is thought to the assist in 
shielding the infectious complete virions from host defences because these subviral particles 
are highly immunogenic and can induce anti-HBs. These subviral particles have been used as 
the basis of many vaccines against hepatitis B (Patient et al., 2007, Patient et al., 2009) 
 
1.1.5 Natural history of HBV 
 
HBV infection is a dynamic process characterised by replicative and non-replicative phases 
based on virus-host interaction. The hepatocytes are principal site of hepatitis viral infection. 
The liver plays an essential role in energy storage and conversion, blood homeostasis, 
chemical detoxification, and immunity to microbial infections (Seeger and Mason, 2000, 
Masson and Littwin, 2002), many of the functional activities of the liver reside in the 
hepatocytes,  which constitutes 70 % of the liver. Therefore this makes them a target of 
hepatotropic viruses such as HBV.  Any disturbance to the liver leads to a wide spectrum of 
clinical presentations ranging from an asymptomatic carrier state to self-limited acute or 
fulminant hepatitis to chronic hepatitis with progression to cirrhosis and hepatocellular 
carcinoma. Viral factors together with the host immune response have been implicated in the 
pathogenesis and clinical outcome of HBV infection (Baumert et al., 2007). The incubation 
period of HBV ranges from six weeks to six months, with clinical symptoms are highly 
dependent on the host (McMahon et al., 1985) 
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1.1.5.1 Acute HBV infection 
 
Acute HBV infection can manifest be asymptomatic but can also manifest as acute hepatitis 
and rarely fulminant liver failure (Sulkowski, 2008).  The most common presentation of 
asymptomatic infections begins with active HBV replication within the hepatocytes, HBsAg 
and HBeAg become detectable in blood within two weeks of infection before anti-HBcAg 
can be detected in the liver and may persist up to 8 weeks. Anti-HBc occurs early and 
decreases after 6 months. Anti-HBs appear after the decrease of HBV replication.  Acute 
hepatitis varies in severity from mild to fulminant, which occurs rarely, in 1-2 % of acute 
hepatitis patients. The clinical  manifestations of HBV infection are  age dependant.  In adults 
HBV is generally acute and self-limiting whilst it is mild in children and neonates (Fattovich, 
2003).  In neonates, clinical manifestation generally do not occur, in children aged 1-5, only 
5% to  15 % develop clinical symptoms, whereas 33% to 50 % of older children and adults, 
develop symptomatic infections (Mahoney, 1999). Manifestations of acute hepatitis include 
high HBV DNA and serum transaminases (ALT) levels, which can  persist.  Acute infections 
usually  resolve within 6 months (McMahon et al., 1985).  Clinical symptoms of acute 
hepatitis  include  fever, anorexia, nausea, malaise, vomiting, jaundice, dark urine, clay-
coloured or pale stools, and abdominal pain (Mahoney, 1999, Sulkowski, 2008).  
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Figure 1.4: Natural history of acute Hepatitis B virus infection (modified from (McMahon 
and Spach, 2005). 
 
1.1.5.2 Chronic HBV infection 
 
Chronic HBV infection is defined as the persistent presence of HBsAg in the serum of an 
individual for 6 months or longer and the absence of anti-HBc immunoglobulin (IgM) 
(Mahoney, 1999). Persons with chronic HBV infection are at substantially increased risk of 
developing chronic liver diseases, including cirrhosis and primary HCC.  The risk of 
developing chronic HBV infection ranges inversely with age: up to 90% in infants infected in 
perinatal period, between 25 to 50 % of children between the ages of 1 and 5 and 10 % in 
older children and adults (Mahoney, 1999).  Chronic disease factors such as renal failure, 
HIV infection, and diabetes are associated with of developing chronic infection (Mahoney, 
1999)  
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Three phases of chronic HBV infections are described: the immune tolerant phase has almost 
normal liver histology,   high HBV DNA levels and HBeAg positivity, this phase is usually 
recognised in children and adolescents; the immune clearance phase is characterised by 
seroconversion from HBeAg to anti-HBe, followed by active hepatic inflammatory response 
and fibrosis,  with fluctuating ALT levels and lastly, the residual phase, which is 
characterised by low HBV DNA and normal ALT levels (Sulkowski, 2008). Spontaneous 
reactivation is often seen during the course of chronic HBV infection and involves the 
reappearance of HBeAg and/or HBV DNA and a rise in serum ALT levels, after a period in 
which they are low or negative.(Baumert et al., 2007)  
 
Persons with chronic HBV infection are generally classified as having one of three histologic 
patterns on liver biopsy: chronic persistent hepatitis, chronic active hepatitis, and cirrhosis.  
Cirrhosis is an irreversible condition in which regenerative nodules and fibrosis cause liver 
injury and may lead to development of HCC (Mahoney, 1999). The degree of histologic 
injury is hardly reflected by the symptoms, and persons with severe chronic liver disease are 
often asymptomatic appearing to be healthy with normal ALT levels until later in the course 
of their illness  
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Figure 1.5:  Natural history of HBV chronic infection (modified from Calabrese, et al, 2006) 
 
1.1.6 The HBV genome Organization 
 
The HBV viral genome is the smallest known fully replication competent genome among 
animal viruses. It has a genome size that is genotype dependent, varying from 3182 to 3248 
nt (Kramvis et al., 2005a) (Jilbert et al., 2002). The HBV genome of an infectious virion is a 
relaxed circular double stranded DNA (rcDNA) consisting of an almost complete negative 
DNA strand of 3.2 kb and the shorter positive strand which varies in length (~1.6-2.8 kb) 
(Mahoney, 1999). The circular structure of the genome is maintained by the terminal 
redundancy, r, of 8 nt of the negative DNA strand and the incomplete positive strand with a 
variable 3’. The 5’ end of the negative DNA strand is covalently linked to the terminal 
protein of the viral DNA polymerase, while the 5’ of the positive DNA strand is capped by an 
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18 nt RNA oligonucleotide which is derived from the pre-genomic RNA obtained during 
replication (Jilbert et al., 2002, Kann, 2002). 
 
The HBV genome encodes four overlapping open reading frames  that encode for seven viral 
proteins:  the core (C), polymerase (P), surface (S), and the X ORF’s (figure 1.4) coded by 
the negative DNA strands whilst the positive strand is non-coding (Kann, 2002). All HBV 
regulatory elements are encoded within the protein coding sequences. Transcription results in 
formation of preC/pregenomic, preS1, preS2/S and X mRNA transcripts, which are modified 
by 3’ polyadenylation and 5’ cap (Moolla et al., 2002).  A single polyadenylation signal 
terminates transcription at a common at 3’ end for all four transcripts, however, the 5’ends 
vary depending on the location of each of the four ORF promoters (preC/pregenomic, preS1, 
preS2/S and X promoters) initiating transcription by binding of the RNA polymerase II 
(Zentgraf, 2002, Jilbert et al., 2002).  In addition, two enhancers: enhancer I and enhancer II 
and the cis –acting negative regulatory elements regulate transcription (Moolla et al., 2002). 
The C ORF encodes for the core protein (HBcAg) and the e antigen (HBeAg), P encodes for 
the viral polymerase (reverse transcriptase), the S encodes for 3 surface proteins: SHBs, 
MHBs and LHBs. X encodes for the HBx trans-activator (figure 1.4) (Kann, 2002, Jilbert et 
al., 2002, Zentgraf, 2002) 
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Figure 1.6: Structure and organization of the HBV genome presenting the plus (+) and 
minus (-) sense,  showing four main mRNA transcripts indicated by the arrow bars and their 
corresponding protein products , DR1 and  DR2 also illustrated on the 5’ and 3’ ends (Lai and 
Locarnini, 2008). Reproduced with permission of International Medical Press, © 2008 
 
1.1.7 The viral gene products 
 
Transcription of the overlapping HBV ORF’s generates four mRNA transcripts (figure 1.4 
and 1.5): the 3.5 kb pre-genomic, 2.4 kb S1, 2.1 kb S2 and 0.7 kb X mRNA transcripts. The 
3.5 kb pregenomic mRNA is a template for translation of the core protein (HBeAg and 
HBcAg) and the viral polymerase (reverse transcriptase). The 2.4 kb and 2.1 kb mRNA 
transcripts encode the preS1 (large), preS2 (middle) and major surface proteins (HBsAg) 
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respectively which are essential for envelopment of the nucleocapsid. The 0.7 kb serves a 
template for the additional gene products during natural infection,  the  HBV X protein and 
the  hepatitis e antigen (HBeAg), their function is unknown (Moolla et al., 2002, Mahoney, 
1999, Seeger and Mason, 2000). 
 
 
Figure 1.7: Four HBV primary transcripts that translates into seven HBV proteins 
 
1.1.7.1 Precore/core ORF 
 
The precore/core (C) open reading frame contains two start codons coding for two 
overlapping proteins, the HBeAg and the HBcAg (Mahoney, 1999), depending on the start 
(AUG) codon used. A 21.5 kDa core protein is synthesized when a translation start at the 
second start codon is used. This can be either 183, 185 or 195 amino acids in length 
depending on viral genotype (Kann, 2002, Locarnini et al., 2003). When translated, the 
HBcAg is targeted to the endoplasmic reticulum where it is cleaved and assembles into the 
nucleocapsid or viral capsid. The core protein has two functional distinct domains, the amino 
acid terminal (1-144) of the core protein are needed for assembly of the nucleocapsid and the 
arginine-rich C-terminal domain (amino acids 150-164) at end of the protein mediates nucleic 
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acid binding, encapsidation of the pgRNA and stabilization of the capsid protein (Locarnini et 
al., 2003). Assembly of the HBcAg into the icosahedral subviral particles requires formation 
of dimers or subunits, these are stabilized through two disulfide bonds, followed by assembly 
of 120 dimers into a single shell with a diameter of 32 nm and a T3 symmetry  or   a diameter 
of  36 nm consisting of T4  symmetry with 240 core proteins dimers (Seeger and Mason, 
2000, Kann, 2002). 
 
The first translation start codon of the precore/core ORF 87 nucleotides upstream of the core 
initiation site results in the HBeAg  This is a 25 kDa protein consisting of a 19 amino acid 
(aa) pre-C domain and a core polypeptide chain of 183 or 185 aa. The pre-C region serves as 
a signal peptide that targets the precursor to the ER, where the N-terminus is cleaved to yield 
a 22-23 kDa protein. 34 aa of the protein is cleaved further from the carboxyl terminus in the 
Golgi apparatus into a mature product of 15-18 kDa HBeAg,  which is secreted into the blood 
(Harrison, 2006, Kann, 2002). The HBe protein is essential for the establishment of persistent 
infection (Locarnini et al., 2003) and is an indicator of high viral replication and infectivity 
(François et al., 2001).  It is also thought to be a tolerogen (Chen et al., 2004). 
 
1.1.7.2 Polymerase ORF 
 
The polymerase is the second protein to be translated from the pgRNA and longest ORF. It is 
845 aa in length. Its translation start codon is 600 nt down stream of the 5’ end of the RNA 
encoding a 90 kDa protein (Kann, 2002); (Seeger and Mason, 2000). The P gene, with 834–
845 codons, has at least four domains: N-terminal domain, spacer, polymerase, and carboxyl 
terminal domain.  The N-terminal domain (1-183 aa at the N-terminus of the protein) codes 
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for the terminal protein (TP), which is involved in minus-strand DNA synthesis and is 
required for the pregenomic RNA encapsidation. 
 
 The spacer covers aa 184 -354 and serves as an intervening domain of the N-terminus and 
the reverse transcriptase (RT) with no specific recognized function (Locarnini et al., 2003). 
The polymerase domain encodes for the reverse transcriptase (RT) extends through aa 355-
694. It incorporates the YMDD motif; this is the catalytic domain essential for reverse 
transcriptase activity (Seeger and Mason, 2000, Yokosuka and Arai, 2006). The carboxyl 
terminal domain encompasses aa 695-844. It encodes for a ribonuclease (RNase H) that 
serves as a reverse transcriptase RNase H activity endowed domain  that cleaves RNA in the 
RNA-DNA hybrids during reverse transcription (Seeger and Mason, 2000). The RNase H 
domains also plays a role in viral RNA packaging, in optimizing priming of minus-strand 
DNA synthesis, and in elongation of the minus-strand viral DNA. The polymerase domain 
also  encodes at least two T cell epitopes within its catalytic domains at amino acid residues 
107 to 115 and 227 to 235 (Locarnini et al., 2003). 
 
1.1.7.3 X ORF 
 
The X ORF is a highly conserved region and encodes a 17 kDa polypeptide of 154 amino 
acids (HBx) translated from the 0.7 kb mRNA (Locarnini et al., 2003, Moolla et al., 2002). 
Its function during natural viral infection is unknown. It is an essential component of the 
infectivity process in vivo (Seeger and Mason, 2000). The HBx is known to activate various 
signalling pathways (AP-1, NF-κB) 
 in vitro and to bind p53.  
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1.1.7.4  Envelope ORF 
 
 
The envelope ORF encodes the hepatitis surface antigen (HBsAg). HBV has three distinct 
surface/envelope proteins, LHBs, MHBs and SHBs which can be distinguished by three 
domains (figure 1.6).  The envelope ORF posseses three separate translational start sites but 
has the same stop codon (UAA). The longer preS1 mRNA of 2.4 kb  encodes the LHBs, the 
first start codon of the shorter S mRNA (2.1 kb) encodes the MHBs  and the SHBs is 
transcribed using the second start codon of the 2.1 kb S mRNA and is the most abundant 
(Locarnini et al., 2003).  
 
Synthesis of the surface proteins occurs in the ER. Relative distribution of the three surface 
proteins varies between virions, filaments and spheres. More LHBs is found in virions and 
filaments than in spheres. Over expression of LHBs results in retention within the ER which 
prevents particle formation (Kann, 2002). The envelope proteins exist in two forms, the 
glycosylated and unglycosylated form and are covalently linked to the other viral proteins by 
disulphide bridges formed by cysteine residues (Seeger and Mason, 2000). 
 
 
 
Figure 1.8:   The three domains of HBsAg, The single 2.4-kb RNA makes LHBs while the 
various 2.1- kb mRNAs translate MHBs and SHBs (modified from Locarnini et al., 2003) 
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1.1.7.4.1 Small envelope protein 
 
SHBs protein is referred to as the major surface (HBsAg) protein is composed of 226 amino 
acids and the most abundant protein in all three HBV-associated particles.  It is 24 and 27 
kDa in its unglycosylated and glycosylated form respectively. 50%-60% of the small 
envelope protein is folded into α-helices numbered I – V, by 4-5 lengths of hydrophobic 
amino acids (Figure 1.7a). The first helix (I) is located between amino acids 11-29, crosses 
the ER membrane and translocates the upstream sequence into the ER lumen (Kann, 2002). 
The next amino acids 30 to 79 comprise the first polar hydrophilic domain, which is the 
major cytoplasmic loop and afterwards localised in the virus interior. The next helix II , 
signal II covers aa residues 80-98 and  is also inserted in to the ER membrane to mediate 
translocation of downstream sequences and directed to the core particle (Kann, 2002). 
 
Second hydrophilic domain of HBsAg is after helix II; it consists of 70 aa and covers residues 
99 to 168. This region contains a high number of cysteine residues, which are cross-linked 
with each other by disulfide bonds to form a loop configuration, the major antigenic 
determinant of HBsAg, known as the ‘a’ determinant (Locarnini et al., 2003).  This region is 
exposed on the surface of the virus and subviral particles containing the antigenic 
determinants,  the epitope  (“a” determinant) are able to elicit virus-neutralising antibodies 
(anti-HBs) following immunization (Seeger and Mason, 2000, Locarnini et al., 2003) 
 
The ‘a’ determinant is common for all nine serological subtypes and is defined by a threonine 
or isoleucine at position 126 of HBsAg. The serological subtypes are differentiated by amino 
acid substitutions at positions 122 and 160 of HBsAg  and are used to distinguish between 
serotypes d/y and w/r (Kramvis et al., 2005b).  During an infection, antibodies against all 
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determinants will be produced, those against the ‘a’ determinant entirely will be able to 
protect against other HBV serological subtypes, and hence the ‘a’ determinant is clinically 
the most crucial. This has lead to use of the HBsAg as the basis of many vaccines against 
HBV (Torresi, 2002).  Downstream of helix II is helix III, passing through the ER, following 
helices IV and V spanning the ER membrane (Kann, 2002). 
 
1.1.7.4.2 Medium envelope protein 
 
The MHBs pre-S2 domain consists of the S and a 55-amino-acid N-terminal extension (figure 
1.7 B) and is 281 aa in length.  It is a minor component of the virion or HBs particle. PreS2 is 
N-glycosylated with a glycan at amino acid 4 and may additionally have an O-glycan at 
position 37 in HBV genotypes B-F.   Two glycosylated forms can be distinguished: gp33 and 
gp36.  Ninety percent of preS2 molecules are modified further by the acetylation of their N-
terminal methionines (Kann, 2002).  The role of MHBs is not well understood, however,  the 
central part of the Pre-S2 domain carries the major antigenic epitope and the region between 
amino acids 3 and 16 has the ability to bind polymerized human serum albumin but the 
significance of this binding is unknown (Locarnini et al., 2003) . 
 
1.1.7.4.3 Large envelope protein 
 
The LHBs is the largest surface protein with 389-400 aa residues and it consist of  three 
domains, pre-S1, pre-S2, and S (figure 1.6), in addition to an extra 108-119 amino acids on 
its N-terminus, depending on subtype/genotype and is glycosylated (Locarnini et al., 2003).  
It shares carboxyl terminal sequence with the MHBS and SHBs surface proteins (figure 1.7 A 
and C).  
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 LHBs constitute only 10-30 % of the total surface proteins which is an important ratio  for 
virion assembly and secretion (Kann, 2002). When the LHBs is localised in the ER and 
exposed on the virion surface (Schädler and Hildt, 2009) (figure 1.7 C), it is accessible to 
antibodies, potential receptors and proteases, or in the hepatocyte cytosol (Kann, 2002),  
followed by  localisation in the virion interior (figure 1.7 D) where it is involved in 
envelopment of the mature core particles,essential for viral assembly (Kann, 2002). The N-
terminal end of the pre-S domain is myristylated, this is not required for virion formation and 
release but is essential for virion infectivity. The LHBs has important antigenic sites for both 
B and T cells that appear to play critical roles in recovery from viral infection. The coding 
regions  at amino acids 27 to 35, 72 to 78, and 95 to 107 are very crucial immunogenic 
epitopes within the LHBs protein (Locarnini et al., 2003). 
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Figure 1.9: Topological models of the three HBV surface proteins:  (A) Small surface 
protein (SHBs), (B) middle surface protein (MHBs). (C) Large surface protein (LHBs) with 
ER localized preS1 domain, (D) large surface protein with cytoplasmically localized preS. 
The α-helices are numbered I-V. N- or O-glycosylations are marked N- or O-glyc. The top of 
each picture represents the lumen of the ER/pre Golgi compartment, whilst the bottom 
corresponds to the hepatocytes cytosol or interior of the virus. (Kann, 2002). Reproduced 
with permission of International Medical Press, © 2008 
 
1.1.8 HBV life cycle and genome replication 
 
1.1.8.1 Entry into hepatocytes 
 
The hepatocytes are the primary site for HBV viral DNA replication.  It is generally believed 
that HBV interacts with a specific, yet unidentified,  cell-surface receptor.  The virus enters 
the cell via  receptor-mediated endocytosis of virus into the hepatocytes (Scaglioni et al., 
1996). Following entry into the host cell, the viral envelope is thought to fuse with the 
endosome, resulting in the release of the viral nucleocapsid into the cell cytoplasm (Jilbert et 
al., 2002). Before entering the nucleus, the nucleocapsid is disassembled on the cytoplasmic 
side of the nuclear membrane, thus allowing the viral DNA to enter the nucleus and initiate 
replication where the conversion into covalently closed circular DNA (cccDNA) occurs 
(figure 1.7) (Scaglioni et al., 1996, Schädler and Hildt, 2009).  
 
1.1.8.2 Conversion of rcDNA to cccDNA 
 
At the end of viral entry process, the rcDNA is delivered into the nucleus and converted into 
a nuclear, episomal cccDNA by an endogenous DNA polymerase activity. This involves 
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completion of positive plus (+) strand DNA synthesis, removal of the bond that links the 
polymerase to the 5’ end of the negative (-) strand DNA, removal of the RNA primer from 
the 5’ end of (+) strand DNA and ligation of the DNA ends (Scaglioni et al., 1996). The 
cccDNA represents the central intracellular intermediate in viral replication and serves as a 
template for all transcripts involved in protein production and replication (Jilbert et al., 2002).   
 
1.1.8.3 pgRNA transcription from cccDNA 
 
By utilizing the host cell RNA polymerase II, the cccDNA is used as a transcriptional  
template for the  pre-genomic RNA (pgRNA) of 3.5 kb in length, which encodes the core and 
polymerase proteins (reverse transcriptase), the 2.4 kb and 2.1 kb transcripts,  which encode 
the surface envelope proteins, whilst a 0.7 kb transcript encodes the X-protein (Mahoney, 
1999). Transcription of these four proteins is initiated by different gene promoters; the 
enhancer II/basal core, large surface antigen, major surface antigen and enhancer I/X, 
respectively (Scaglioni et al., 1996). 
 
1.1.8.4 Reverse Transcription 
 
HBV replicates its genome by reverse transcription of the pgRNA, which is characterised by 
terminal repeats at the 5’ and 3’ ends which include the direct repeats: DR1 at both ends, 
DR2 at the 3’ terminal and the stem loop RNA packaging signal  (ε) (Moolla et al., 2002).. 
First, the pgRNA-polymerase complex is packed into subviral packages composed of HBcAg 
subunits, whereas the viral polymerase binds to the encapsidation signal ε,  which is a cis-
element on the pgRNA. This is aided by three host chaperone proteins:  p23 and heat shock 
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protein 70 (Hsp70) aid the binding of the polymerase to ε, and Hsp60 is required in the 
activation of the viral polymerase (Kramvis and Kew, 1998, Seeger and Mason, 2000).  
 
The ε-polymerase interaction, also activates reverse transcription, where the binding of the 
polymerase acts as a primer at the 5’UUC3’ motif within the bulge of the 5’ ε,   initiating the 
synthesis of the first 3 nt of the negative DNA strand 5’GAA3’. The formed Pol-
oligonucleotide complex is then translocated into DR1 at the 3’ end of the pgRNA and 
continues with the rest of the negative DNA strand synthesis till the 5’ end of the pgRNA 
(figure 1.6)(Siegel, 2007). The elongation of the negative DNA strand occurs simultaneously 
with degradation of the pgRNA by RNAse H activity, which leaves only the last 18 bases 
including the DR1 motif. This translocates s to the DR2 motif and serves as a primer for the 
positive DNA strand synthesis. Elongation of the positive strands continues to the 5’ end of 
the negative DNA strand, this includes a 9 base terminal redundancy sequence 
complementary to the 3’ end of the negative strand DNA. This results in the elongating 5’ 
end of the positive DNA strand being transferred to the 3’end of the negative DNA strand and 
therefore circularising the genome, and finally leading to rcDNA synthesis (Jilbert et al., 
2002, Seeger and Mason, 2000, Scaglioni et al., 1996, Schädler and Hildt, 2009).  
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Figure 1.10: Viral DNA replication by reverse transcriptase. DR1 and 2: Direct repeat 
sequences (modified from 
http://www.stanford.edu/group/virus/1999/tchang/replication.htmm, Accessed November 
2010) . 
 
1.1.8.5 Capsid maturation, Envelopment and budding 
 
The nucleocapsid containing the newly the synthesised rcDNA is either recycled back to the 
nucleus for the conversion into cccDNA for synthesis of more viral particles or enveloped 
selectively,  before budding off the cell. The envelopment occurs in the Golgi apparatus, 
where the nucleocapsid are translocated from the cytoplasm Golgi complex through the ER to 
acquire an ER membrane containing lipids and the three viral surface proteins (SHBs, MHBs 
and LHBs). In the Golgi complex, the surface proteins are glycosylated, this is followed by 
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release  of mature virions into the bloodstream for infection of more cells (figure l.7)  (Seeger 
and Mason, 2000).  
 
 
 
Figure 1.11 HBV life cycle. The cycle commences with attachment of the infections virion 
on to the target cell receptor via the preS1 domain of LHBs protein. Uncoating is followed by 
relocation of the nucleocapsid into the nucleus where the rcDNA is converted into cccDNA. 
The cccDNA serves as template for transcription of mRNA and the pgRNA. The mRNAs 
proceed to the cytoplasm and translated into viral proteins. The pgRNA is reverse transcribed 
into rcDNA which is either converted into cccDNA or translocated across the endoplasmic 
reticulum and coated surface proteins and ends with release into the bloodstream. (modified 
from http://prolacmalaysia.com/page.php?10) 
27 
 
1.2 HBV GENOTYPES 
 
A genotype is generally defined as the genetic constitution of an organism. In viruses, it  is a 
form in which the genomic sequence of a virus that is replication competent has stabilized 
after a prolonged period of time (Kramvis et al., 2005b, François et al., 2001). HBV 
replicates by reverse transcription of the pregenomic RNA using a viral-encoded polymerase 
that lacks proof-reading activity. The genome may evolve at an estimated error rate of 1.4 - 5 
x 10-5 nucleotide substitutions/site/year (Fares and Holmes, 2002, Orito et al., 1989, Gunther 
et al., 1998), which results in a wide virus heterogeneity (Ramos et al., 2007). As a result of 
this genetic variability, genotypes of HBV have been identified (Kramvis et al., 2005). 
defined by  the inter-genotypic differences of more than 7.5% in the complete nucleotide 
sequence (Okamoto et al., 1988, Norder et al., 1992b). To date, phylogenetic analysis of the 
HBV genome has lead to recognition of nine genotypes of HBV: A to D (Norder et al., 1994, 
Okamoto et al., 1988), genotype E to F (Norder et al., 1994, Naumann et al., 1993, Norder et 
al., 1992b), genotype G (Stuyver et al., 2000), genotype H (Arauz-Ruiz et al., 2002) 
genotype I(Olinger et al., 2008)  and more recently a tenth  genotype J has been proposed 
(Tatematsu et al., 2009).  
 
Before identification of HBV genotypes, HBV was classified according to serotypes. four 
major serological subtypes were identified based: adw, adr, ayw  and  ayr (Norder et al., 
1992a, Okamoto et al., 1987) and further into 10 serological subtypes (ayw1, ayw2, ayw3, 
ayw4, ayr, adw2, adwq, adr, adrq− and adrq+ ), depending on the amino acid substitutions on 
the antigenic determinant at positions 122, 127 and 160 (Kramvis et al., 2005b) .  There is a 
limited relationship between the HBV genotypes and the serological subtypes and their 
geographical distribution (Table 1). 
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Table 1.1 Relationship between genotypes and serotypes and their geographical distribution § 
Genotype Serotype  Geographical distribution 
A adw2, ayw1, ayw2, adw4 North western Europe, USA, sub-Saharan 
Africa, East Africa and central Africa , Japan, 
and the Philippines  
B adw2, ayw1, adr Indonesia, South and East Asia, Vietnam, 
Brazil, Indonesia, the Philippines and 
Venezuela 
C adr, adrq+, adrq- ayr, adw, 
adw2, ayw2, ayw3, adwr 
Venezuela, Korea, China, Japan Polynesia, 
Vietnam, East Asia, Japan, the Philippines, 
Tibet Australia [Aborigines] and Japan 
D ayw,  ayw3, ayw4, adw3 West, Central  and, East Africa, India 
Mediterranean area,  Middle East,  USA and 
Central America  
E ayw4 West Africa, Nigeria, Western and Central 
Africa 
F adw4, adw4q−, adw2, ayw4 South and Central American Hispanics, France, 
Alaska, 
G adw2 France, Germany, USA and the United 
Kingdom 
H adw4 Northern part of Latin America, Central 
America and Mexico 
§adapted from (Kramvis et al., 2005b), adw2 occur in many parts of the world 
 
Subgenotypes of five genotypes (A, B, C, D, and F) have been identified (Kramvis et al., 
2005b), based on more than 4% divergence in the complete genome (Norder et al, 2004)  The 
HBV genotypes  and subgenotypes show a distinctive geographical distribution (figure 4.). 
This may change over time as a result of human migration patterns or due to specific risk 
behaviour such as injection drug use and men having sex with men (Ramos et al., 2007, 
Günther, 2006). Genotype A predominates in the USA and South America, North and Middle 
Europe, Southern Africa, Asia  (Kramvis et al., 2002, Kramvis and Kew, 2007a). Genotype B 
and C are dominant  in mainland and South East Asia, Japan, Australia and the Pacific 
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Islands. Genotypes B and C have been  subdivided into six and five subgenotypes,  
respectively (Tanaka et al., 2005, Kramvis et al., 2008, Sakamoto et al., 2006, Sugauchi et 
al., 2002).  
 
 Genotype D occurs in many places in the world, including France, Germany, India, Alaska , 
USA, Canada, West and South Africa ( figure 4) where the transmission route is mainly 
horizontal (Owiredu et al., 2001, De Maddalena et al., 2007, Sugauchi et al., 2002). 
Genotype E only occurs in Africa and is closely related to genotype D (Takahashi et al., 
2000, Mulders et al., 2004, Shibayama et al., 2005). Genotype F is indigenous in Central and 
South America and Polynesia; it has only four subgenotypes (Huy et al., 2006, Arauz-Ruiz et 
al., 1997, Devesa et al., 2008). Genotype G has been found in Germany, North America, 
France and the UK (Kato et al., 2002, Günther, 2006). Genotype H occurs in Central 
America,  Mexico and Canada (Arauz-Ruiz et al., 2002). Recently genotype I have been 
identified in Vietnam, South East Asia and North East India (Huy et al., 2008, Arankalle et 
al., 2010, Hannoun et al., 2000, Yu et al., 2010). The proposed Genotype J was isolated from 
a Japanese HCC patient from Borneo. It is  most genetically related to a non-human primate 
(Tatematsu et al., 2009).   
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Figure 1.12.  Geographical distributions of the eight hepatitis B virus genotypes, the numbers 
next to the pie charts are the number of isolates genotyped. Adapted from Kramvis et al, 
2005. Reproduced with permission of Prof. A. Kramvis 
 
1.2.1 African HBV genotypes and subgenotypes 
 
Africa is an area of very high endemicity for HBV, with three  genotypes A, D and E 
predominating (Kramvis and Kew, 2007b), with genotypes B and C sporadically detected 
(Zekri et al., 2007). Genotypes A is found mainly in southern and eastern Africa, genotype  D 
in northern Africa and genotype E Central and West Africa (figure 1.5) (Sbai et al., 2007, 
Borchani-Chabchoub et al., 2000).  Despite the importance of HBV infection in Africa up to 
five years ago there was a limited number of HBV genotyping studies in Africa 
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1.2.1.1  Genotype A 
 
HBV genotype A genomes have a characteristic 6 nucleotide (nt) insert at the carboxy-
terminal end of the core gene, which is not found in the other genotypes. It has distinctive 
sequence characteristics in all ORFs and in the transcriptional regulatory elements. Genotype 
A was the first genotype in which subgenotypes were recognised (Bowyer et al., 1997b). 
Subgenotype A1 was first identified in HBV isolates from South Africa using phylogenetic 
analysis of preS2/S sequences (Bowyer et al., 1997b). However, later studies then identified 
subgenotype A1 in Malawi,   Mexico, Brazil, Philippines, India and Nepal (Sugauchi et al., 
2003, Sánchez et al., 2002, Estacio et al., 1988, Sugauchi et al., 2004) 
 
Subgenotype A1 has distinct sequence characteristics in all ORF’s and transcription 
regulatory elements that may affect both replication of the virus and the expression of its 
proteins, which differentiates it from subgenotype A2 (Kimbi et al., 2004).  Compared to 
subgenotype A2, subgenotype A1 has a greater mean nucleotide divergence, indicating that 
subgenotype A1 has been endemic to the South African Black population and has a long 
natural history within the population (Kimbi et al., 2004). Subgenotype A2 has been reported 
to be widely distributed in European countries and the USA (Olinger et al., 2006). 
Characterization of additional strains has lead to the identification of subgenotype A3 in the 
Cameroon, Democratic Republic of Congo and Gabon, Central African Republic. 
Subgenotype A3 characteristic feature include a recombination of a non-overlapping short 
fragment of the polymerase RT domain with genotype E (Kurbanov et al., 2005),  found in 
one of the Cameroonian strains. The complete genome analysis of subgenotype A3 suggests a 
long natural history within the native population of Cameroon (Kurbanov et al., 2005, 
Makuwa et al., 2006).  Recently, subgenotype A4 and A5 have been isolated in Mali and 
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Nigeria respectively (Olinger et al., 2006). More recently, Subgenotypes A6 and A7 have 
been proposed (Hübschen et al., 2010, Pourkarim et al., 2010). Subgenotype A6 strains have 
been isolated from African–Belgian patients originating from Congo and Rwanda (Pourkarim 
et al., 2010) and subgenotype A7 strains have so far only been found in Rwanda and Western 
Cameroon (Hübschen et al., 2010).   
 
1.2.1.2  Genotype D 
 
Genotype D is found in many places around the world. In Africa, it has been described in 
Egypt, Morocco, Tunisia, West and South Africa (Borchani-Chabchoub et al., 2000, Zekri et 
al., 2007, Sbai et al., 2007) . Genotype D is 3 182 nucleotides in length and is characterized 
by a 33-nucleotide deletion at the N terminus of the preS1 region. Genotype D also has been 
divided into five subgenotypes: D1 to D5 (De Maddalena et al., 2007, Chandra et al., 2009) 
isolates of subgenotype D1 are mainly from the Middle East. Subgenotype D2 were mostly 
from Germany and India. Subgenotype D3 was from Alaska, Sweden France and South 
Africa. And lastly subgenotype D4 isolates were from Somalia, and Oceania (Sugauchi et al., 
2002).  Subgenotype D5 has been described in East India (Chandra et al., 2009). 
Recombination has been reported between genotype A and D over the non-overlapping 
regions of the S and P open reading frames (Owiredu et al., 2001, De Maddalena et al., 
2007). 
 
1.2.1.3  Genotype E 
 
Genotype E is restricted to Africa and mainly found in central and West Africa (Mulders et 
al., 2004, Kao, 2002) (figure 5). A feature of genotype E genome isolates is that they have a 
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3-nucleotide deletion at the amino terminus, However, Genotype E does not separate from 
genotype D in the X and C ORFs (Kramvis et al., 2005b, Kidd-Ljunggren et al., 2002), and 
its existence has been questioned (Kidd-Ljunggren et al., 2002, Bowyer and Sim, 2000) . 
Genotype E has been isolated form chimpanzees; this has lead to speculations that genotype 
E may have once been a chimpanzee hepadnavirus, however, no direct transmission could be 
established (Takahashi et al., 2000). 
 
 
 
Figure 1.13. Hepatitis B virus (HBV) genotypes A, B, C, C and D distribution across the 
African continent. (Kramvis & Kew, 2007).  Reproduced with permission of Prof. A. 
Kramvis 
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1.2.2 Clinical relevance of the HBV genotypes 
 
Studies have suggested possible pathogenic and therapeutic differences among HBV 
genotypes. Many of the studies have been done comparing and contrasting genotypes 
molecular and clinical similarities and differences. In Southern Africa genotypes A, D, and E 
of HBV circulate, with genotype A dominating (Kew et al., 2005).  From earlier studies, a 
higher prevalence of genotype A in patients with HCC compared with asymptomatic carriers 
was deduced (Zeng et al., 2005, Thakur et al., 2002). A South African study showed a 4.5-
fold increased risk for HCC and an earlier age of cancer diagnosis (on average, 6.5 years 
younger) in HBV carriers infected with genotype A compared with non-A genotypes (Kew et 
al., 2005). Subgenotype A1 was found to have a lower frequency of HBeAg positivity 
compared to genotype D (Kramvis and Kew, 2007a) .Genotype A is known to induce chronic 
hepatitis more often and hold much higher response to interferon treatment than genotype D 
(Thakur et al., 2002, Kao, 2002).  
 
 An Indian study suggested that HBV genotype D is associated with more severe diseases and 
may predict the occurrence of HCC in young patients (Thakur et al., 2002).In a European 
study, genotype D was found to be more associated with earlier HBeAg sero-conversion, 
with much higher incidence of HCC when compared to genotype A. In addition, genotype D 
had a stronger resistance to anti-viral drugs. (Schaefer, 2005). Genotype E, which 
predominantly  occurs in Africa is reported to be associated  with progression to chronic 
HBV carrier during the childhood in West Africa (Schaefer, 2005) 
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1.2.3 HBV genotypes in HIV co-infected individual 
 
There are very few studies documenting HBV genotypes in HIV infected individuals.  In a 
number of  European studies,  genotype A has been found to be the most predominant 
followed by genotype D and genotype  E (Pérez-Olmeda et al., 2003, Soriano et al., 2010, 
Ramos et al., 2007, Cooley et al., 2003). Despite the high prevalence of both HBV and HIV 
in Africa, the genotypes prevailing in African HIV infected individuals are unknown. As far 
as we can ascertain, this is the first study to examine the HBV genotypes in South Africa. 
 
1.3  HBV MUTANTS: DISTRIBUTION AND DISEASE PROGRESSION 
 
Considering the compact and overlapping arrangement of the HBV genome together with the 
lack of proof reading activity by the viral reverse transcriptase, the host and anti-viral 
pressure the mutation rate occurring in the HBV genome is relatively high. The nucleotide 
substitution rate, per site per year, has been estimated to be 1.4×10−5 to 5×10−5 (Fares and 
Holmes, 2002, Kramvis and Kew, 2005, Sugauchi et al., 2000, Okamoto et al., 1987). The 
mutation errors in genomic replication are of great importance in viral evolution, they allow 
the virus mutants to escape host immune responses (immune/vaccine escape mutants) and be 
able to resist antiviral treatment pressures (drug resistant mutants) (Bonhoeffer and 
Sniegowski, 2002). Therefore this results in changes which bear on the progression of the 
disease, virus replication and expression of viral proteins. 
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1.3.1 Precore/core mutants 
 
The core promoter directs transcription of the 3.5 kb mRNA: the pgRNA and the precore 
mRNA (pre-C mRNA). The pgRNA is translated into the core protein (HBcAg) and the viral 
polymerase and serves as a template for reverse transcription after being packaged into the 
virus core particles (figure 1.7). Therefore the precore/core core promoter is very important 
because it plays a central role in viral DNA replication and morphogenesis (Tiollais et al., 
1985, Mayerat et al., 1999).  The pre-C mRNA is translated into the pre-C/C fusion protein 
that is post-translationally modified into HBeAg, which is not required for viral replication, 
and may be involved in induction of immune tolerance (Milich and Liang, 2003).  The core 
promoter (CP) consists of the Basic core promoter (BCP) and the upper regulatory region 
URR. 
 
The PC gene contain important elements that are very crucial for viral replication: the start 
site for pgRNA synthesis, DR1 and the ε signal, hence its sequence variation within this 
region is limited. The CP encompasses nt 1814 to 1901.  One of the most important mutations 
occurring in this region is the G1896A stop codon mutation, which occurs within the ε signal 
bulge within the priming region. This mutation truncates the precore/core protein into a 28 aa 
peptide and completely abolishes HBeAg expression (Carman et al., 1989). The presence of 
A1896 depends on C1858 or T1858, which is genotype specific. Genotypes A and H have 
C1858, genotype B, D and E have T1858 and the other genotypes  can have either of the 
variants (Rodriguez-Frias et al., 1995). In genomes with T1858, the A1896 mutation  
stabilises the ε signal, resulting in a an enhanced  stability of the, pgRNA promoting the 
initiation of DNA synthesis (Lok et al., 1994). The C1858 with the mutation A1896 results in 
a wobble pair, which destabilises the ε signal and is therefore detrimental to reverse 
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transcription initiation (Lok et al). Therefore the A1896 mutant is not common in genotypes 
with C1858.  The G1896A variant is less prevalent in chronic carriers from South Africa 
because genotype A, which  T1858 , is prevalent.  
 
In a South African study, when the precore region of HBV isolated from sera and HCC 
tumour tissue was analysed,  the most common missense mutation was G1862T (Kramvis et 
al., 1997a, Kramvis et al., 1998b).  This mutation was more prevalent in HBeAg-negative 
than HBeAg positive asymptomatic carriers and HCC patients (Kramvis et al., 1997a, 
Kramvis et al., 1998b).   This mutation results in a valine to phenylalanine mutation in the 
precore region of HBV causing intracellular retention and impaired secretion of HBe-antigen 
(Chen et al., 2008b). 
 
1.3.2 Basic core promoter mutants 
 
The BCP region  encompasses nt 1724 to 1849 (Kramvis and Kew, 1999). The region 
contains DR1 and cis-acting elements that independently direct transcription of pre-C mRNA 
and pgRNA: The A-T rich regions control transcription of pre-C mRNA and pgRNA. 
Mutations within this region may severely reduce pgRNA and may dysregulate viral gene 
expression contributing to disease progression.  The most frequently described mutations 
within this region are the A1762T together with G1764A. This double mutant is accompanied 
by a reduced level of hepatitis B e antigen (HBeAg) expression (Takahashi et al., 1995, 
Laskus et al., 1995).  These mutations are often seen in chronic patients or fulminant hepatitis 
than asymptomatic carriers (Kramvis and Kew, 1999, Baptista et al., 1999). They have been 
isolated from sera, liver and tissue samples from patients with HBV-related HCC. The double 
mutation has been often seen in genotypes that have C1858 which prelude favours 
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development of pre-C stop codon mutation G1896A. The A1762T  G1764A double mutation 
together with 1753 mutation may be a marker for advanced liver disease (Kramvis and Kew, 
1999). Mutations in the region 1753 -1757 together with the A1762T G1764A have been 
detected in isolated with HCC and fulminant hepatitis (Kramvis and Kew, 1999).  
 
Other mutaions that occur within the BCP regions include the G1809T C1812T. In the Kozak 
region, which is upstream of the precore start codon (UAG) , 80 % of Sounth African blacks 
hobour a double or triple mutation  on this region (1809-1812  (Baptista et al., 1999). The 
translational product of the core gene HBeAg antigen requires  initation of translation from 
the UAG upstream of the core gene on the precore messenger RNA. The triple mutaion on 
this region was found to reduce translational initiation and therefore the  reducing HBeAg 
expresssion, while theh double mutation was found to slightly enhance HBeAg expression 
(Ahn et al., 2003). 
 
1.3.3 Complete Surface gene mutants 
 
The surface gene has a vital role in the life cycle of the hepatitis B virus and infectivity of the 
virus.  The HBsAg protein contains the cysteine-rich “a” determinant (nt 99 to 169)  it is this 
region that is recognised by antibodies that are elicited by active hepatitis B vaccination and 
by anti-HBs antibody present in hepatitis B immune globulin  (Torresi et al., 2002). 
Mutations of the surface gene antigen lead to problems in the antigenicity and 
immunogenicity of the HBsAg. This results in immune escape mutants and false HBsAg 
negatives (Iacomi et al., 2009). 
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The most described mutations in the S gene are the immune/ vaccine escape mutants. These 
are the mutants on the ’a’ determinant These vaccine escape mutants can infect vaccinated 
individuals and are prevalent in countries with high endemic rates of HBV infection and with 
established HBV vaccination programs (Torresi et al., 2002). The most common mutants 
described is the G145R (Gly→Arg) and  Q129R  (Gln →Arg) (Szomor et al., 2008, Carman 
et al., 1990),Other ‘a’ determinant mutations that have been reported include P120L (Pro→ 
Leu), T123N (Thr →Asn), T126 N (Thr→Asn),  M133L (Met→Leu), and D144 A/G 
(Asp→Ala/Glu)  (Sheldon et al., 2006, Torresi, 2002) . 
 
1.3.4 Polymerase mutants 
 
The polymerase gene is the longest gene of HBV, spanning almost 80% of the genome and 
overlapping the three other genes (surface, core and x) (Tiollais et al., 1985), with the 
polymerase gene overlapping the envelope gene. Mutations in the catalytic domain of the 
polymerase gene can affect the amino-acid sequence of the envelope protein (HBsAg) and 
vice versa. since the ‘a’ determinant overlaps the major catalytic regions of the viral 
polymerase protein from amino acid 454 to 524 and known as domains A and B (Locarnini, 
1998). 
 
Mutations in the polymerase are lethal to the virus because this region encodes for the reverse 
transcriptase DNA polymerase and   RNase H activity, packaging of the pgRNA, which are 
important activities in the viral life cycle. Mutations in the polymerase region mostly result 
following the use of nucleoside analogues during therapy.  
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The most reported analogue resistance is to lamuvudine (LMV), which is a member of a class 
of antiviral nucleoside analogues that inhibit hepadnavirus replication specifically by 
inhibiting viral reverse transcriptase by terminating viral DNA synthesis (Allen et al., 1998, 
Iacomi et al., 2009). LMV induces resistance mutations in the major catalytic region of the 
reverse transcriptase known as the YMDD motif (tyrosine-methionine-aspartate-aspartate 
motif) (Torresi, 2002, Ramos et al., 2007). Common  LMV resistance mutations in this 
region include the triple mutation, rtV173L+ rtL180M + rtM204V (figure 1.13)  (Zoulim and 
Locarnini, 2009). These mutant viruses are functional and pathogenic but less efficient than 
wild-type viruses. Because of the overlapping orientation between the polymerase and the 
HBsAg, the amino acid changes in the HBsAg selected by LMV alter the antigenicity of the 
HBsAg and therefore the ability of anti-HBs antibody to recognise and bind to the protein 
(Torresi et al., 2002). M204I and L180M/M204I produce I195M and W196S in the HBsAg. 
Other HBsAg overlapping polymerase region mutations selected by  LMV include the  
mutants E164D and M198I (figure 1.12) (Torresi, 2002) . 
 
1.4 HBV AND HIV CO-INFECTION 
 
1.4.1 Characteristics of co-infection 
 
The co-infection of HBV with HIV is very common due to shared mode of blood-borne 
transmission (Audsley et al., 2010, Thio et al., 2002, Alter, 2006).  An estimated 4 million 
out of the 40 million HIV-infected people worldwide are co-infected with HBV (Fix et al., 
2007)  Hepatitis B virus is an important cause of mortality and morbidity among HIV 
infected persons (Thio, 2003, Bloquel et al., 2010). A number of studies from around the 
world have found that the prevalence of HBV infection among HIV-positive individuals is 
41 
 
significantly higher than in HIV-negative individuals (Burnett et al., 2005, Bloquel et al., 
2010). Higher frequencies of liver disease have been reported amongst the co-infection and 
exceedingly high incidence rates of serological markers of prior or active HBV infection have 
been reported in HIV-infected populations and have been estimated to be between 10- 80 % 
depending on the population being studied and geographic region, (Bloquel et al., 2010, Fix 
et al., 2007, Burnett et al., 2005),  For example, the prevalence of co-infection in injection 
drug user population is 5 % to 10 %, in South African region, 20 % prevalence has been 
reported (Soriano et al., 2008),  9%, 16.9 %, 25.9 %, and 73 %  has been reported in small 
cohorts  the geographical regions: Tanzania, Malawi, Nigeria and Uganda respectively 
(Peters, 2007). 
 
HIV induced immune suppression have been reported to have serious and harmful effects on 
the natural history, physiology, diagnosis and therapeutic responses to hepatitis B virus 
(Kottilil, et al, 2005).   These include a lower response rate to HBV vaccination, higher 
chances of developing chronic diseases after HBV exposure, higher HBV DNA levels and 
more profound liver disease experienced as a result of the chronic HBV infection and the 
presence of the HBV pre-core mutants tends to present a more aggressive and more 
prolonged liver disease and more hepatoxicity under antiretroviral treatment regimens. HBV 
has been associated with increased risk of progression of immunodeficiency progress of HIV 
infection into AIDS and a premature death (Firnhaber et al, 2005, 4).  
 
1.4.2 HBV-HIV co-infection impact on disease progression and treatment 
 
HIV has a significant impact on the natural history of HBV infection. Patients co-infected 
with HIV and HBV are particularly at risk of hepatitis B reactivation (Peters, 2007, Burnett et 
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al., 2005). In these patients, the mortality rate due to liver related disease is 19-fold higher 
than those with HIV mono infection and   are up to six-fold more likely to develop chronic 
hepatitis B than are HIV-negative individuals (Thio, 2009). 
 
Cirrhosis is more common in HIV-HBV co-infection in spite of lower ALT levels than in 
HBV mono-infection. There is some evidence that lower CD4_ T cell counts are associated 
with increased risk for HCC in HBV-HIV coinfected individuals, (Thio, 2009).  HIV 
infection also decreases the rate of HBeAg clearance up to five-fold and increases the level of 
HBV replication as manifested by higher HBV DNA levels (Sulkowski, 2008) . In a study 
done by Colin al, it was found that HIV infection is associated with a higher level of HBV 
replication and a higher risk of cirrhosis in homosexual men with chronic hepatitis B (Colin 
et al., 1999). Even HIV-infected persons who acquire protective antibody to hepatitis B 
surface antigen (anti-HBs) remain at risk for loss of anti-HBs and subsequent reactivation 
latent HBV infection  (reverse seroconversion) (Firnhaber and Ive, 2009) 
 
Occult hepatitis B infection is also seen more commonly in HIV-positive individuals, in this 
case, co-infection may escape diagnosis, especially in resource-limited countries where it is 
not possible to measure the HBV DNA viral load or use nucleic acid tests, which are more 
expensive. This may lead to an increased risk of hepatic cirrhosis caused by hepatitis B and 
of hepatic-related deaths in HIV patient if not treated (Firnhaber and Ive, 2009, Mphahlele et 
al., 2006).  
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1.4.3 Management and treatment of HBV-HIV co-infection 
 
Co-infection with hepatitis B and HIV can influence antiretroviral treatment and prognosis of 
both diseases. HIV infection can complicate the diagnosis of hepatitis B because spontaneous 
reverse seroconversion marked by the disappearance of anti-HBs and reappearance of HBsAg 
can occur, especially if CD4T cell counts are less than 200 cells/mm, therefore allowing 
reactivation of HBV infection (Thio, 2009). In a South African study occult HBV infection 
was found in 22.1% of  HIV positive patients. This increased prevalence of occult hepatitis B 
in HIV-positive patients clearly supports that HIV infection is one of the risk factors for false 
negatives in  serological HBsAg tests (Mphahlele et al., 2006).   
 
The guidelines for the South African HIV Comprehensive Care, Management and Treatment 
(CCMT) programme do not include viral hepatitis studies. Therefore, hepatitis B serological 
tests are done only if serum amino transferases are elevated in the absence of other known 
causes (Firnhaber et al., 2008). In South Africa, LMV is currently one of the three drugs in 
the highly active anti-retroviral therapy (HAART) and is active against both the HIV and 
HBV. LMV has been reported to cause high rate LMV-selected resistant variants and more 
predominantly in patients infected with HBV  genotype A (Iacomi et al., 2009). 
 
1.4.4 HBV-HIV co-infection in the Sub-Saharan Africa 
 
HBV infection has long been recognised as highly endemic in Southern Africa including 
Botswana, South Africa, Zambia and Zimbabwe with many of the studies conducted among 
black Africans (Botha et al., 1984, Dibisceglie et al., 1986). Majority  of the people have 
been exposed to HBV horizontally as children and by the  time they are  exposed to HIV 
infection for the first time are already protected from HBV infection, or are chronic carriers 
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of HBV (Burnett et al., 2005).  HIV in South Africa is a major public health problem with 
HIV seroprevalence as high as 65% depending on population, geographical location and 
ethnicity (Kleinschmidt et al., 2007). 
 
Most of the research from around the globe conducted in areas of low HBV endemicity found 
that the prevalence of HBV infection among HIV-positive individuals is significantly higher 
than in HIV-negative individuals (Horvath and Raffanti, 1994, Bodsworth et al., 1991, Hess 
et al., 1989), mainly as a result of shared transmission routes. In South Africa few studies 
have been conducted and the generated is slightly divergent from that of the world. In study 
done in an urban government clinic, an HBV-HIV prevalence rate of 5 % was found, 
determined by the surface antigen serology. A 50 % prevalence of markers for previous 
exposure to HBV the HIV sero-positive patients was also reported (Firnhaber et al., 2008, 
Firnhaber et al., 2009). The  alanine aminotransferase (ALT) and aspartate aminotransferase 
were within the normal range in 84% and 57% of these HBsAg-positive patients  and most of 
the patients had low HBV DNA viral load (Bisceglie A. M. Di et al., 2010, Firnhaber et al., 
2008, Firnhaber et al., 2009).  
 
In another study by Mphahlele et al, HBsAg antigen was more prevalent in HIV-positive that 
HIV-negative individuals, with 22.1 % HBsAg negativity in HIV-positive compared to 2.4% 
of HIV-negative individuals and there indicating that in a South African setting, HIV 
infection might be a  risk factor for occult hepatitis B (Mphahlele et al., 2006). Lukhwareni et 
al, investigated the prevalence of HBV in sera from HIV positive South African patients 
initiating antiretroviral therapy (ART). Sixty three percent of the study patients had evidence 
of past of HBV infection, with 40.6 % of the patients having detectable HBV DNA, 22.9 % 
were HBsAg positive and were significantly associated with high HBV Viral loads.  Twenty 
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three percent of the HBsAg negatives had occult infections. This study demonstrated that 
HIV/AIDS patients initiating ART in South Africa have chronic or acute HBV infections and 
that HIV is a factor for occult HBV infection in a South African setting (Lukhwareni et al., 
2009).  
 
1.5 RATIONALE, AIMS AND OBJECTIVES OF THE STUDY  
 
It is evident that the epidemiology, the global distribution of the different genotypes of the 
HBV and the modes of transmission vary around the world (Kramvis et al., 2005b, 
Shibayama et al., 2005, Orito et al., 2001) and that data obtained outside Africa cannot be 
extrapolated to the Southern African context. Many of the areas where HBV is highly 
endemic overlap with areas having high rates of HIV infection (Idoko et al., 2009). Many of 
the HBV/HIV co-infection studies have been conducted in areas of low endemicity, with very 
few studies being conducted in regions where both HBV and HIV are endemic. 
 
Therefore it is important that HBV and HIV co-infection is studied locally in order to 
generate data that are relevant to South Africa, so that clear insight and understanding on the 
effect of the two viruses on the disease/s can be obtained.  Although the genotypes in HIV-
negative individuals have been studied extensively in South Africa (Kew et al., 2005, 
Kramvis et al., 2005b, Kramvis and Kew, 2007a), there is great paucity of data of the 
genotypes prevailing in HIV-infected individuals.  
 
The main objective of the study was to molecularly characterise HBV isolates from HIV 
infected South Africans from two distinct locations, namely, Helen Joseph Hospital, an urban 
46 
 
hospital in Johannesburg and Shongwe Hospital, a rural hospital in Mpumlanga Province.  
The aims of the study include the following:  
1. Amplification and molecular characterization of the basic core promoter/precore 
and complete surface region of HBV 
2. Genotyping of HBV 
3. Identification of mutations 
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Chapter 2:  MATERIALS AND METHODS  
 
2.1 0VERVIEW AND ORGANISATION OF THE STUDY 
 
Figure 2.1. An overview of the study participants recruited and the methods used in the 
Helen Joseph Hospital study.  Numbers in bold refer to the region in HBV genome from the 
EcoR1  site. 
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Figure 2.2: Flow diagram of methodology followed in the Shongwe Hospital study. Numbers 
in bold refer to the region in HBV genome from the EcoR1  site. 
 
2.2 STUDY PARTICIPANTS AND SERUM SAMPLES 
 
2.2.1 The Helen Joseph Hospital Urban Cohort 
 
For the urban cohort, serum samples from participants recruited from Helen Joseph Hospital 
in Johannesburg, South Africa were utilised. Blood samples were obtained with informed 
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consent from 17 individuals who have been confirmed to be HBV and HIV positive from a 
previous study (firnhaber et al, 2008). Blood was drawn before initiation of HAART 
(baseline) and at six months after initiation of HAART. 
 
2.2.2 The Shongwe Hospital Rural cohort 
 
For the rural cohort, the samples were collected from participants attending a rural hospital, 
Shongwe Hospital in Malelane in Mpumalanga Province, East of South Africa. This area is 
located between the Mozambique and Swaziland Borders.  Three hundred HIV positive 
patients were recruited before initiation of  HAART.  Of these patients, 114( 38 %)  were 
male and 186 (62 %) were female patients with CD4 cell counts less than 200 cells/mm3. 
Only patients older than 18 years of age, with signed informed consent were allowed to 
participate in the study. The study participants were from the surrounding area, as well as 
from Swaziland and Mozambique.  
 
2.3 ETHICS CLEARANCE 
 
For the Helen Joseph Study, Ethics Clearance certificate was obtained by Dr. C. Firnhaber 
(Medical: M050620). An umbrella Ethics clearance certificate for the Shongwe Hospital 
study was obtained By Prof. A Kramvis from the Witwatersrand Human Research Ethics 
Committee (Medical: M080450 ). Ethics clearance for this research project was also obtained 
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from Witwatersrand Human Research Ethics Committee (Medical: M090414) and from the 
Mpumalanga Provincial Health Research and Ethics Committee. (appendix C). 
 
2.4 DNA EXTRACTION 
 
Serum obtained from patients was used to extract HBV DNA using the QIAamp® DNA 
Blood Mini Kit (QIAGEN, GmbH, Hilden, Germany), as per manufacturer’s instructions. 
This kit allows for the purification of total DNA, free of protein, nucleases and other 
contaminants or inhibitors, from blood, plasma, serum or other body fluids. 
 
Before starting, the samples and the buffers were equilibrated to room temperature, and a 
heating block was pre-heated to 56ºC. An aliquot of 200 µl of the serum sample was added to 
a 1.5 ml Eppendorff tube, together with 20 µl QIAGEN Protease (Proteinase K). 200 µl 
Buffer AL was then added to the sample and the mixture pulse-vortexed for 15 sec to mix, 
followed by 10 min incubation at 56ºC. A volume of 200 µl of absolute ethanol was then 
added to the sample and again mixed by pulse-vortexing for 15 sec. The mixture was then 
carefully applied to a QIAamp Spin Column and centrifuged at 8 000 rpm for 1 min. The 
column was placed in a clean collection tube and 500 µl Buffer AW1 added. Centrifugation 
was again carried out at 8 000 rpm for 1 min and the column placed in a clean collection tube. 
After addition of 500 µl Buffer AW2, the QIAamp Spin Column was centrifuged at 14 000 
rpm for 3 min. To eliminate any chance of Buffer AW2 carryover, an optional centrifugation 
step was carried out for an extra min at 14 000 rpm. The QIAamp Spin Column was then 
placed in a sterile 1.5ml Eppendorff tube, 75 µl best quality water (BQW) added directly to 
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the column and incubated for 5 min at room temperature. The DNA was eluted by 
centrifugation for 1 min at 8 000 rpm and stored at -20ºC until needed. In addition to the 
serum sample, a negative control consisting of BQW was included in the extraction 
procedure to check for contamination. 
 
2.5 POLYMERASE CHAIN REACTION (PCR)   AMPLIFICATION 
 
PCR is a highly specific and sensitive method designed to amplify large quantities of a DNA 
sequence without the use of cloning. The basic three steps of PCR involve a denaturation step 
in which double stranded DNA is denatured to single stranded DNA by heating to 94ºC, an 
annealing step in which the primers anneal to either side of the target sequence via their 
complementary bases and lastly, the extension of the target sequence by a DNA polymerase. 
Each of the aforementioned steps occurs at different temperatures in a thermal-cycler, 
resulting in an exponential increase in the target DNA.  
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Table 2.1: Primer sequences used for the PCR. 
Region 
Amplified 
Primer 
Name 
Primer Sequence * 
 
Nucleotide 
Position in 
HBV Genome* 
C
o
m
pl
et
e 
S-
re
gi
o
n
 
S1F  5’TCA ATC GCC GCG TCG CAG AAG ATC TCA ATC 3’  nt 2410-2439  
S1R  5’TCC AGA CCX GCT GCG AGC AAA ACA 3’  nt 1314-1291  
S2F  5’AAT GTT AGT ATT CCT TGG ACT CAT AAG GTG GG 3’  nt 245–2482  
S2R  5’AGT TCC GCA GTA TGG ATC GGC AGA GGA 3’  nt 1254 -1286 
P7
/p
8 
230F  5’TCA CAA TAC CGC AGA GTC T 3’ nt 230  -249 
800R  5’AAC AGC GGT ATA AAG GGA CT 3’ nt  800-820 
P7  5’ GTG GTG GAC TTC TCT CAA TTT TC 3’  nt 25 -278  
P8  5’ CGG TAT AAA GGG ACT CAC GAT 3’  nt 796-776  
BC
P 
BCP1F  5’ GCA TGG AGA CCA CCG TGA AC 3’  nt 1606-1625  
BCP1R  5’ GGA AAG AAG TCA GAA GGC CAA 3’  nt 1955-1974  
BCP2F  5’ CTA AAG AGG ACT CTT GGA CT 3’  nt 1653-1672  
BCP2R  5’ GGC AAA AAA AGA GTA ACT A 3’  nt 1940-1959  
 
* Nucleotide position of HBV adw genome (GenBank accession number (AY233276), where 
position 1 is the EcoRI cleavage site. 
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2.5.1 Partial S region PCR  
 
A nested PCR was carried out to amplify a small region  of the HBsAg of HBV(256 to 796  
from the EcoR1 site). This PCR was carried out on the MyCycler thermal cyclerTM PCR 
machine (BioRad, USA).  The first round PCR consisted of 22.5 µl of reaction mixture 
containing 15.4 µl BQW, 2.5 µl 10X NH4 Buffer, 1.5 µl 25 mM MgCl2, 0.5 µl 40mM 
dNTP’s (10 mM each dNTP), 1.25 µl each of the outer primers, 230F and 800R, respectively 
(Table 2.1), and 0.1 µl Promega Taq DNA Polymerase (Promega, Madison, WI) in a 0.2 ml 
PCR tube. To this mixture, 2.5 µl of DNA was added to bring the total reaction mixture to 25 
µl.  
 
PCR cycling for the first round involved 40 cycles of denaturation at 94ºC for 60 sec, 
annealing at 55 ºC for 1 min and extension at 72ºC for 2 min. An aliquot of 5 µl of the above 
reaction was then added to a second round mixture containing; 32.3 µl BQW, 5 µl 5.0 NH4 
µl, 1.5 µl,   25 mM MgCl2, 1 µl 40 mM dNTP’s (10 mM each dNTP), 2.5 µl each of the inner 
primers P7 and P8, respectively (Table 2.1), and 0.2 µl Promega Taq DNA Polymerase 
(Promega, Madison, WI) in a 0.2 ml PCR  tube. The second round cycling profile consisted 
of 40 cycles of the same cycling conditions as the first round. 
 
2.5.2 Basic Core Promoter (BCP)/precore PCR 
 
A nested PCR was carried out to amplify the basic core promoter/ precore region of HBV. 
This PCR was carried out on the MyCycler thermal cyclerTM PCR machine (BioRad, 
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USA)First round PCR consisted of 22.5 µl of a reaction mixture containing 15.4 µl BQW, 2.5 
µl 10X NH4 buffer, 1.5 µl 25 mM MgCl2, 0.5 µl 40mM dNTP’s (10 mM each dNTP), 1.25 µl 
each of the outer primers, BCP1F and BCP1R, respectively (Table 2.1), and 0.1 µl Promega 
Taq DNA Polymerase (Promega, Madison, WI) in a 0.2 ml Eppendorff tube. To this mixture, 
2.5 µl of DNA was added to bring the total reaction mixture to 25 µl. 
 
PCR cycling for the first round involved 40 cycles of denaturation at 94ºC for 60 sec, 
annealing at 55 ºC for 1 min and extension at 72ºC for 2 min. An aliquot of 5 µl of the above 
reaction was then added to a second round mixture containing; 32.3 µl BQW, 5 µl 5.0 NH4 
buffer µl, 1.5 µl,   25 mM MgCl2, 1 µl 40 mM dNTP’s (10 mM each dNTP), 2.5 µl each of 
the inner primers BCP2F and BCP2R, respectively (Table 2.1), and 0.2 µl Promega Taq DNA 
Polymerase (Promega, Madison, WI) in a 0.2 ml PCR  tube. The second round cycling profile 
consisted of 40 cycles of the same cycling conditions as the first round. 
 
2.5.3 Complete S-region PCR 
 
A nested PCR was carried out to amplify the entire S region of HBV (preS1/S2/S region). 
First round PCR consisted of 22.5 µl of a reaction mixture containing 9.25 µl BQW, 12.5 µl 
Qiagen Hot Start master mix, outer primers, S1F and S1R, respectively (Table 2.1), in a 0.2 
ml Eppendorff tube. To this mixture, 2.5 µl of the DNA was added to bring the total reaction 
mixture to 25 µl 
 
PCR cycling for the first round involved 40 cycles of denaturation at 94ºC for 60 sec, 
annealing at 65ºC for 1 mins and extension at 72ºC for 3 min. 5 µl of the above reaction was 
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then added to a second round mixture containing; 18.5  µl BQW, 25 µl Qiagen master mix 
0.75 µl each of the inner primers S2F and 1S2R, respectively (Table 2.1), in a 0.2 ml 
Eppendorff tube. The second round cycling profile consisted of 40 cycles of denaturation at 
94ºC for 60 sec, annealing at 66ºC for 1 min and extension at 72ºC for 3 mins. 
 
2.6 DETECTION AND CONFIRMATION OF AMPLIFIED PCR PRODUCT 
 
Following PCR, the resulting DNA products were separated by size via electrophoresis on a 
1% agarose gel containing ethidium bromide (Appendix A). Sizes of PCR products were 
estimated relative to the migration patterns of a 100 bp DNA ladder (Promega, Madison, WI, 
USA) for the BCP/ PC and P7P8 PCR product and a 1 kb DNA ladder (Promega, Madison, 
WI, USA) for the complete surface gene PCR products. Products were visualized by placing 
the gel under ultraviolet light. Images were captured using the GelDoc system (BioRad,   US 
 
2.7 GEL PURIFICATION OF PCR PRODUCT 
 
For some of the complete surface gene amplifications, the PCR products were gel purified 
before being sent for sequencing. The PCR amplicons were electrophoresed on a 0.8% 
agarose gel without ethidium bromide (Appendix A) together with a 1 kb molecular weight 
marker (Promega, Madison, WI, USA). An aliquot of 40 µl of the PCR product was loaded 
onto the gel with 10 µl Loading Buffer containing GelRedTM  nucleic acid  gel stain (Biotium, 
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Hayward, CA, USA) and allowed to run at ~60 volts for 1½ to 2 hours, or once the crystal 
violet in the gel had run about a quarter of the way down the gel. 
 
To excise the PCR product, the buffer was poured off and the gel placed on a fluorescent 
light box to help visualize the fragments. Using a new sterile surgical blade, the band was 
carefully excised from the gel and placed into a sterile 1.5 ml Eppendorff tube. To purify the 
DNA from the agarose  gel, the Zymoclean Gel Recovery KitTM (Zymoresearch, CA, 
U.S.A.).was used The volume of the agarose pieces was estimated by weighing the gel (1mg 
~ 1µl), and 3 times this volume of ADB buffer was added. By periodically shaking the tube 
vigorously and incubating at 55ºC on a hot block, the agarose was completely dissolved in 5- 
10 mins. The melted agarose solution was then added to into a Zymo-Spin Column and 
placed onto a collection tube. This was centrifuged for 30 sec and 200 ul of wash buffer was 
added of wash buffer was added to the column then spun for 30 sec. After repeating the wash 
step once, the Zymo-Spin column was placed on to a clean 1.5 ml eppindorf tube and 10 µl of 
water was added on the column matrix and spun down to elute the DNA. 
 
2.8 LINDH GENOTYPING 
 
Lindh genotyping is a method for genotyping HBV, making use of restriction fragment length 
polymorphism (RFLP), using the restriction enzymes Tsp509I which recognizes AATT and 
HinfI which recognizes GANTC. Following amplification of the HBV DNA with a nested 
PCR using primers 230F and 800R for the first round PCR and  second round primers P7 and 
P8  were used to amplify nucleotides 256 to 796 of the S region, The amplicons were then 
restricted using restriction enzymes HinfI and Tsp509I, in separate reactions, to give the 
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characteristic restriction fragment length polymorphism (RFLP) patterns for the different 
genotypes (Lindh et al, 1997). This genotyping method can be used to discriminate genotypes 
A to H. 
 
2.8.1 RFLP assay for Genotyping 
 
A master mix was prepared for each of the enzymes, Hinf I (Promega, Madison, WI) and 
Tsp 509I (New England Biolabs, Beverly, MA), used for genotyping (Table 2.2) 
 
Table 2.2: Master mixes for genotyping HBV p7/p8 PCR products 
Stock Reagent HinfI  TSP509I 
BQW 2.5 µl 2.5 µl 
10X Buffer 2 µl 2 µl 
Restriction Enzyme 0.5  µl 0.5 µl 
Final volume 5 µl 5 µl 
 
A volume of 5 µl of the each of the master mixes was added to two separate 0.5 ml 
Eppendorff tubes, followed by 15 µl of the PCR product. A drop of sterile mineral oil was 
added to each tube to prevent evaporation of the product. Both reactions were incubated for 3 
hours; Hinf I at 37ºC and Tsp509I at 65ºC. After incubation, the reaction was terminated by 
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the addition of 4 µl loading dye. 10 µl of the sample was then run overnight on a 3% ethidium 
bromide-containing composite agarose gel (Appendix A ) at ~30V, alongside 100 bp and 1 kb 
molecular weight markers (Promega, Madison, WI, USA). The resulting restricted fragments 
were visualized under UV light and images captured using the GelDoc system (BioRad, 
USA) 
 
2.9 SEQUENCING 
  
The amplicons were  prepared for direct sequencing using the BigDye Terminator v3.0 Cycle 
Sequencing Ready Reaction Kit (Applied Biosystems., Foster City, USA) and sequencing 
was performed by the Central Analytical Facility (Marrone et al.), Stellenbosch University,  
South Africa, using the ABI 3130XL Genetic analyser (Applied Biosystems, Foster City, 
CA). Specific sequencing primers were used. BCP sequences were analysed in both the 
forward and reverse directions, whilst the complete S sequences were analysed in 3 
overlapping fragments in forward direction only. 
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Table 2.3. Primers used for sequencing of the BCP/PC region and the complete S region. 
Region Primer Name Sequence 
Nucleotide Position in 
HBV Genome* 
BC
P/
P
C
 
BCP1 5’-GAG GCA TAC TTC AAA GAC TG-3’ nt 1698-1717 
BCP2 5’-AGT AAC TCC ACA GTA GCT CC-3’ nt 1928-1947 
C
o
m
pl
et
e 
S 2497F 5’-TTC CTT GGA CTC ATA AGG TG-3’ nt 2461 – 2480 
3188F 5’-AG TCA GGA AGG CAG CCT AC-3’ nt 3152 – 3170 
591F 5’-ATT GCA CCT GTA TTC CCA TCC-3’ nt 591 – 611 
*From the EcoRI site 
 
2.10 BIOINFORMATICS AND PHYLOGENETIC ANALYSIS 
 
Both complete surface and the precore/core DNA sequences were assembled and aligned 
manually using GeneDoc (http://evolution.genetics.Washington.edu, 1995) The sequences 
were compared with corresponding African Genotype A sequences of HBV from GenBank. 
Multiple sequence alignments and nucleotide divergence calculations were carried out using 
Dambe (Xia, 2000). The alignments were fed into PHYLIP (Phylogeny inference package) 
version 3.5c (Page, 1996) DNAML (maximum likelihood) alone and DNADIST 
consecutively with NEIGHBOR (neighbour-joining) were used to generate dendograms. 
SEQBOOT, DNADIST and NEIGBOR were be used for bootstrapping of 1 000 data sets.  
CONSENSE were used to compute a consensus tree. TreeView Win 32 version 1.6.1 
software program were to visualize the trees (Page, 1996). 
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Chapter 3: RESULTS 
 
 
 
Figure 3.1A: Summary of the analysis of BCP/PC and complete surface open reading frame 
from Helen Joseph Hospital (HJH) pilot study.   
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Figure 3.1B: Summary of the analysis of BCP/PC and complete surface open reading frame 
from Shongwe Hospital (SH) isolates. 
 
3.1 DETECTION OF AMPLIFIED PRODUCTS 
 
3.1.1  Partial S region PCR 
 
The partial surface gene (256 to 796 from the EcoRI site) was successfully amplified by 
nested PCR.  After amplifying the HBV DNA, a PCR product of  541 bp was visualized  
(figure 3.2). 
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Figure 3.2: Detection of the amplified partial surface gene, (256 to 796 from the EcoRI 
site), visualised as 541 bp PCR product on an ethidium bromides-stained 1 % agarose 
gel (inverted image). 
Lane 1 = 100 bp molecular weight (Promega) 
Lanes 2 and 9 = second round PCR water controls  
Lanes 3 and 8= first round PCR water controls 
 Lanes 4-7= amplified partial surface gene. 
 
3.1.2 BCP/PC amplicons 
 
The basic core promoter/precore region of HBV was successfully amplified from DNA 
extracted from HIV co-infected patients, shown below as 307 bp bands (figure 3.3). 
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Figure 3.3: Detection of the amplified partial BCP/PC region of the HBV genome (1742-
1901 from the EcoRI site) visualised as 307 bp PCR product on an ethidium bromides-
stained 1 % agarose gel (inverted image). 
Lanes = 100 bp molecular weight marker (Promega) 
Lanes 2 and 15 = PCR water control 
Lanes 5, 8, 10 and 12 = unsuccessful amplification of the BCP/PC region (no DNA bands) 
Lanes 3-4, 6-7,9, 11, 13-14 = amplified PCR product 
Lane 16 = PCR positive control 
 
3.1.3 Complete surface gene amplicons 
 
The complete surface gene amplification was successful for most serum samples with high 
HBV viral loads. Successful amplification was shown by detection of a ~2.1 kb DNA band 
(figure 3.4). 
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Figure 3.4: Visualisation of HBV complete surface gene amplicon (2854-835 from the 
EcoRI site) (inverted image).  
Lane 1 = 1 kb molecular weight 
Lanes 2, 24 = BQW control from second round PCR 
 Lanes 3, 23 = BQW control from first round PCR round PCR 
Lanes 4, 8-9, 13-14, 16, 19-21= unsuccessful amplification of the complete surface antigen 
Lanes 5-7, 10-12, 15, 17-18, 22 = successfully amplified complete surface gene from HIV co-
infected samples.  
Lane 25 = PCR Positive control. 
 
3.2 GENOTYPING BY A RESTRICTION FRAGMENT LENGTH 
POLYMORPHISM (RFLP) ASSAY 
 
Genotyping of HBV PCR amplicons from section 3.1.1 (figure 3.2) was performed on the 
Helen Joseph Hospital samples only.  HBV isolated from baseline (prior to HAART 
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initiation) and at six months follow up (after initiation of HAART) were genotyped.  This 
method of genotyping relies on the amplification of a region of the partial S gene of HBV, 
followed by the digestion of the amplicons by restriction enzymes and RFLP analysis. 
Nucleotides 256 to 796 of the surface gene of HBV were successfully amplified from DNA 
extracted from serum samples and detected  by the presence of a 541 bp band on a 1% 
agarose gel (figure 3.2). 
 
The PCR products were then digested using restriction enzymes Hinf I and Tsp 509I, in 
separate reactions. The RFLP pattern for six amplicons at baseline and five at six months 
follow up corresponded to that for genotype A: 274 bp, 252 bp and 15 bp fragments for Hinf I 
and 207 bp, 126 bp, 109 bp, 47 bp and 16 bp fragments for Tsp 509I (Lindh et al., 1997) 
(Figure 3.5), Fragments smaller than 40 bp could not be visualized properly on the agarose 
gel because of their small size.  Six serum samples at baseline and five  out of six followed up 
six months after initiation of HAART  were infected with genotype A. One isolate could not 
be amplified at six months follow up because of the decrease in HBV DNA viral load. 
According to the Lindh genotyping method , one isolate (HJH20B) at six month follow up  
had RLFP pattern corresponding to that of genotype D: 526 bp and  15 bp for HinfI 
restriction and  173 bp, 164 bp and 109 bp for the Tsp 509I restriction (Lindh et al., 1997)  ( 
figure 3.5,  lanes H4 T4). Isolate (HJH01A) had an unusual RLFR pattern and therefore the 
genotype could not be determined using this method.   
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Figure 3.5:  Visualisation of RFLP analysis of partial S-region amplified HBV clones on 
a 3% composite gel,(inverted image).   
Lane M1 = 100 bp molecular weight marker 
Lane M2 = 50 bp molecular weight marker  
Lanes H1, H2, H3, H4 = Hinf I restricted PCR product 
Lanes T1, T2, T3, T4 = Tsp 509I restricted PCR products 
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3.3  DNA SEQUENCING ANALYSIS 
 
The PCR products of both the BCP/PC and the complete surface gene were sent for direct 
sequencing at the Central Analytical Facility (Marrone et al.), Stellenbosch University. The 
generated chromas (figure 3.6) and fasta format DNA sequences were manually edited and 
analysed for mutations and used for phylogenetic analysis. Two isolates were found to have 
mixed genotype sequences. One showed double peaks on the chromatograms (figure 3.7) and 
the other had the BCP/PC sequence with characteristics of genotype A whilst the complete S 
region had characteristics of genotype D and double peaks on part of the S region sequence.  
 
 
 
Figure 3.6: Chromatogram acquired after automated sequencing of the BCP/PC gene of the 
HBV genome from an HBV-HIV co-infected patient, showing the Kozak sequence (1809-
1812 from the EcoR1 cleavage site) preceding the precore start codon of an HBV isolate 
belonging to subgenotype A1. 
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Figure 3.7: Chromatogram generated following direct sequencing of the complete 
surface gene of isolate number S027A. This shows double peaks indicating detection of 
mixed genotypes/ quasispecies of HBV isolated from a single serum sample.   
 
3.4 BCP/PC MUTATION ANALYSIS 
 
3.4.1  Helen Joseph Hospital cohort 
 
HBV DNA from confirmed co-infected patients from the Helen Joseph cohort was extracted 
from 26 samples from baseline and at six month after initiation of HAART. Thirteen BCP/PC 
DNA sequences were analysed for mutations at 10 loci in the region 1750 to 1900 from the 
EcoRI site as described by Kramvis et al, 2008. Eight sequences prior to HAART initiation 
and five sequences at six months follow-up were analysed (figure 3.8). Five sequences of the 
13 had wild type BCP sequences. Four isolates: HJH01A, HJH03A, HJH10A and HJH01B 
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had the A1762T G1764A mutation, with HJH10A having in addition  T1753C, known to 
down regulate HBeAg expression and a HCC marker (Kramvis and Kew, 1999).  Isolate 
HJH05A had the A1762T mutation alone with G1888T.  Two isolates (HJH11B and HJH20B 
had the GCAC at the Kozak sequence (1809-1812) preceding the precore start codon together 
with C1858T and A1888G, characteristic of isolates belonging to genotype D/E (HJH11B 
and HJH20B, highlighted in pink in figure 3.8). All the sequences showed wild type 
sequences at 1802-1803, 1814-1816, 1817-1819, 1862, 1896 and 1899. 
 
         
         
HJH01A : 
HJH02A : 
HJH03A : 
HJH05A : 
HJH07A : 
HJH10A : 
HJH12A : 
HJH01B : 
HJH02B : 
HJH23B : 
HJH11B : 
HJH11A : 
HJH20B : 
         
                                                                                                                
1750 * 1760    * 1770    * 1780    * 1790    * 1800    * 1810    * 1820    * 1830    * 1840    * 1850    * 1860 
AGATTAGGTTAATGATCTTTGTATTAGGAGGCTGTAGGCATAAATTGGTCTGCGCACCATCATCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTACATGTCCCACT
AGATTAGGTTAAAGGTCTTTGTATTAGGAGGCTGTAGGCATAAATTGGTCTGCGCACCATCATCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTACATGTCCCACT
AGATTAGGTTAATGATCTTTGTATTAGGAGGCTGTAGGCATAAATTGGTCTGCGCACCATCATCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTACATGTCCCACT
AGATTAGGTTAATGGTCTTTGTATTAGGAGGCTGTAGGCATAAATTGGTCTGCGCACCATCATCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTACATGTCCCACT
AGATTAGGTTAAAGGTCTTTGTATTAGGAGGCTGTAGGCATAAATTGGTCTGCGCACCATCATCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTACATGTCCCACT
AGACTAGGTTAATGATCTTTGTATTAGGAGGCTGTAGGCATAAATTGGTCTGCGCACCATCATCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTACATGTCCCACT
AGATTAGGTTAAAGGTCTTTGTATTAGGAGGCTGTAGGCATAAATTGGTCTGCGCACCATCATCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTACATGTCCCACT
AGATTAGGTTAATGATCTTTGTATTAGGAGGCTGTAGGCATAAATTGGTCTGCGCACCATCTTCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTACATGTCCCACT
AGATTAGGTTAAAGGTCTTTGTATTAGGAGGCTGTAGGCATAAATTGGTCTGCGCACCATCATCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTTCATGTCCCACT
AGATTAGGTTAAAGGTCTTTGTATTAGGAGGCTGTAGGCATAAATTGGTCTGCGCACCATCATCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTACATGTCCCACT
AGATTAGGTTAAAGGTCTTTGTATTAGGAGGCTGTAGGCATAAATTGGTCTGCGCACCATCATCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTACATGTCCCACT
AGATTAGGTTAAAGGTCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGCGCACCAGCACCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTTCATGTCCTACT
AGATTAGATTAAAGGTCTTTGTACTAGGAGGCTGTAGGCATAAATTGGTCTGCGCACCAGCACCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTTCATGTCCTACT
AGAtTAGgTTAA G TCTTTGTAtTAGGAGGCTGTAGGCATAAATTGGTCTGCGCACCAtCatCATGCAACTTTTTCACCTCTGCCTAATCATCTCTTGTaCATGTCCcACT
      
      
 : 112
 : 112
 : 112
 : 112
 : 112
 : 112
 : 112
 : 112
 : 112
 : 112
 : 112
 : 112
 : 112
      
         
         
HJH01A : 
HJH02A : 
HJH03A : 
HJH05A : 
HJH07A : 
HJH10A : 
HJH12A : 
HJH01B : 
HJH02B : 
HJH23B : 
HJH11B : 
HJH11A : 
HJH20B : 
         
                                       
   * 1870    * 1880    * 1890    * 1900
GTTCAAGCCTCCAAGCTGTGCCTTGGATGGCTTTGGGGC
GTTCAAGCCTCCAAGCTGTGCCTTGGATGGCTTTGGGGC
GTTCAAGCCTCCAAGCTGTGCCTTGGATGGCTTTGGGGC
GTTCAAGCCTCCAAGCTGTGCCTTGGTTGGCTTTGGGGC
GTTCAAGCCTCCAAGCTGTGCCTTGGATGGCTTTGGGGC
GTTCAAGCCTCCAAGCTGTGCCTTGGATGGCTTTGGGGC
GTTCAAGCCTCCAAGCTGTGCCTTGGATGGCTTTGGGGC
GTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGC
GTTCAAGCCTCCAAGCTGTGCCTTGGATGGCTTTGGGGC
GTTCAAGCCTCCAAGCTGTGCCTTGGATGGCTTTGGGGC
TTTCAAGCCTCCAAGCTGTGCCTTGGATGGCTTTGGGGC
GTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGC
GTTCAAGCCTCCAAGCTGTGCCTTGGGTGGCTTTGGGGC
gTTCAAGCCTCCAAGCTGTGCCTTGG TGGCTTTGGGGC
      
      
 : 151
 : 151
 : 151
 : 151
 : 151
 : 151
 : 151
 : 151
 : 151
 : 151
 : 151
 : 151
 : 151
      
 
 
Figure 3.8: BCP/PC region analysis of the Helen Joseph Hospital cohort. A baseline 
isolates and B represents isolates from six month follow up after initiation. Highlighted 
regions indicate regions with mutations.  Blue shows genotype A isolates   and pink indicates 
genotype D or E isolates. Position 1 corresponds to EcoRI cleavage site of HBV genome. 
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3.4.1     The Shongwe Hospital Rural cohort 
 
Table 3.1. BCP/PC region analysis of the Shongwe Hospital Rural cohort  
 
 
 
 
 
 
71 
 
Samples subgenotype 1753 1762 1764 1802-1803 1809-1812 1814-1816 1817-1819 1858 1862 1888 1896 1899
S121A A1 T A G CG TCAT ATG CAA C G A G G
S159A A1 T A G CG TCAT ATG CAA C G A G G
S253A A1 T A G CG TCCT ATG CAA C G A G G
S255A A1 T A G CG TCAT ATG CAA C G A G G
S274A A1 T T A CG TCAT ACG CAA C G G G G
S001A A1 T A G CG TCAT CTG CAA C G G G G
S009A A1 T T A CG TCAT ATG CAA C G A G G
S016A D1/E T A G CG GCAC ATG CAA T G G A G
S022A A1 T A G CG TCAT ATG CAA C G A G G
S042A D1/E T A G CG GCAC ATG CAA T G G A G
S048A A1 T A G CG TCAT TTG CAA C G A G G
S070A A1 T A G CG TCAT CTG CAA C G T G G
S100A A1 T A G CG TCAT ATG CAA C G A G G
S109A A1 T A G CG TCAT ATG CAA C G A G G
S126A A1 T A G CG TCAT ATG CAA C G A G G
S148A A1 C T A CG TCAC AAG CAA C G G G G
S167A A1 T A G CG TACT ATG CAA T G A A A
S180A A1 T T A CG TTCT ATG CAA C G G G A
S256A A1 T A G CG TCAT ATG CAA C G A G G
S300A A1 T A G CG ACAT ACG CAA C G G G A
S027A A2 T A G CG TCAC ATG CAA T G G A G
S029A A1 T A G CG TCAT ATG CAA C G A G G
S032A A2 T A G CG GCAC ATG CAA C G G A G
S039A A1 T A G CG TCAT ATG CAA C G A G G
S044A A1 T A G CG TCAT ATG CAA C T A G G
S053A D1/E T A G CG GCAC ATG CAA T T G G G
S060A A2 T A G CG p ATG CAA C G G G G
S061A A1 C T A CG TCTT ATG CAA C G T G G
S083A A1 T A G CG TCAT ATG CAA C G A G G
S094A A2 C A G CG ACAC ATG CAA C G G G G
S107A A1 T A G CG TCAT ATG CAA C G A G G
S110A A1 T A G CG TCAT CTG CAA C G A G G
S123A A1 T A G CG TCAT ATG CAA C G A G G
S128A A1 T A G CG TCAT ATG CAA C G A G G
S131A A1 T A G CG TCAT ATG CAA C G A G G
S132A A1 T A G CG TCAT ATG CAA C G A G G
S130A A1 T A G CG TCAT CTG CAA C G C G G
S162A A1 T A G CG TCAT ATG CAA C G G G G
S173A A1 T A G CG TCAT ATG CAA C T A G G
S184A A1 C T A CG TCTT ATG CAA C G T G G
S187A A1 T A G CG TCAT ATG CAA C T A G G
S193A A1 T A G CG TCTT ATG CAA C G A G G
S217A A2 T A G CG GCAC ATG CAA C G G G G
S219A A1 T A G CG TCAT ATG CAA C T A G G
S221A A2 C T A CG GCAC CTG CGA C T A G G
S240A A1 T A A CG TCCT ATG CAA C G A G G
S246A A1 T A G CG TCAT ATG CAA C T A G G
S249A A2 T A G CG GCAC ATG CAA C G G G G
S264A A1 C T A CG TCAT ATG CAA C G G G G
 
  HBeAg positie 
   HBV active infection 
  HBV occult infection 
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Out of 300 HIV infected individuals 72 were found to be co-infected with HBV using 
detection of HBV DNA in at least two regions of the HBV genome.   The BCP/precore 
region of 51 of these samples was successfully amplified by nested PCR and sent for 
sequencing.  Forty nine DNA sequences were generated, assembled, aligned and analysed by 
GeneDoc software. From the sequence analysis of the 49 BCP/PC sequences it subgenotypes 
could be deduced according to Kramivis et al, 2008. Three isolates (SH16A, SH42A and 
SH53A) had HBV subgenotype D/E with Kozak sequence GCAC at nt 1809-1812, 1888G 
and 1858T.  Seven isolates (SH27A, SH32A, SH60A, SG94A, SH217A, SH221A and 
SH249A) were subgenotype A2 with BCP/PC characteristic Kozak sequence GCAC at 1809-
1812, 1888G and 1858C.   Thirty nine sequences found to be subgenotype A1 with Kozak 
sequence TCAT (or mutant) at nt 1809-1812, 1888A and 1858C/T (figure 3.9) . 
 
 Of the 49 cases, 5 were HBeAg-positive and the remaining 41 HBeAg-negative.  Four 
(S121A, S159A, S253A, S255A) of the five isolates from HBeAg positive cases did not  
show any  mutations in the BCP/precore region,  which can abolish or down regulate the 
expression of the HBeAg. They had wild type sequences at positions 1762A/ 1764G, 1809-
1812 (TCAT Kozak), 1862G and 1888A relative to the consensus for subgenotype A1 of 
HBV. 
 
The 44 BCP/precore sequences derived from HBeAg negative individuals were analysed for 
mutations, which are known to abolish the synthesis of HBeAg or down regulate its 
expression. This may be at transcriptional, translational, or at post translational level. 
mutations A1762T G1764A known to down regulate HBeAg expression at transcriptional  
level occurred in eight isolates (S274A, S009A, S148A, S180A, S061A, S184A, S221A and 
S264A), with five cases occurring together with the T1753C and two belonging to 
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subgenotype A2.  The Kozak mutations affecting the expression of HBeAg at translational 
level were found in nine isolates, with two occurring together with the precore initiation 
codon (1814-1816). Four (S027A, S94A, S148A and S300A) had double mutation and five 
isolates (S061A, S180A, S184A, S194A and S240A) had triple mutation. In addition, seven 
isolates had the precore initiation codon, which completely abolishes HBeAg expression at 
translational level. The G1896A mutation occurred in five isolates and in four cases it 
occurred together with the C1858T mutation. 
 
 The G1862T, which interferes with post-translational modification HBeAg-precursor and 
abolishes HBeAg expression occurred in seven HBsAg negative isolates and none in the 
HBsAg positive isolates (p<0.05) (figure 3.10).  Position 1888 had a single nucleotide 
substitution mutation in 20 cases, with 3 having the unusual G to T mutation and two cases 
having in addition the G1899A mutation. All sequences had wild type sequences at positions 
1802-1803 and 1817-1819, Only 13 isolates out of the 49 BCP/PC sequences had wild type 
sequences at region 1750-1900. 
 
Of the 39 samples belonging to subgenotype A1, for which the BCP/precore region was 
successfully sequenced, 20 were from HBsAg-positive and from 21 HBsAg-negative sera.  
The frequency of the various BCP/precore mutations was compared between the two groups.  
There was no difference in the frequency of the mutations except for G1862T, which 
occurred more frequently in the HBsAg-negative (figure 3.9, Table.3.1). 
 
 
74 
 
 
Figure 3.9: Mutations present in the BCP/PC region of the HBV subgenotype A1.  
* G1862T statistically significant (P< 0.05).  
§ Wild type: 1802-1803 (GC); 1809-1912 (TCAT); 1814-1816 (ATG). 
 
3.5 PHYLOGENETIC ANALYSIS  
  
DNADIST was used consecutively with NEIGHBOR (neighbour-joining) to determine the 
genotypes of all the isolates from both Helen Joseph and Shongwe Hospital, dendograms 
generated using all complete surface gene sequences together with representative sequences 
derived from Genbank belonging to genotypes A-I. The trees were then visualized using Tree 
View Win 32 software program (figure 3.10). All the isolates clustered with subgenotype A1, 
except for isolate S055A which clustered with genotype D (figure 3.10).  Nine isolates were 
serological subtype of ayw2 (blue) and the remaining 33 were serological subtype adw2 
(pink) 
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Figure 3.10. Phylogenetic relationship of the hepatitis B virus S open reading frame (position 
2854-835 from the EcoR1 site) of Shongwe Hospital (number with “S” prefix) and Helen 
Joseph Hospital (numbered with “HJH” prefix).  Isolates from HBV-HIV co-infected isolates 
prior to ARV treatment are marked with suffix “A” and those at six months following 
treatment with “B”. Trees established using neighbour-joining method. Bootstrap statistical 
analysis was performed using 1 000 data sets and the numbers on the nodes indicate the 
percentage of occurrences. 
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Figure 3.11.  A circular phylogenetic tree comparing the South African subgenotype A1 
complete S region with Asian and African subgenotype A1 obtained from GeneBank 
(designated by accession numbers), established using neighbor-joining. Red: African cluster, 
Blue: Central African cluster and Green: South eastern African/Asian cluster ( ‘Asian” 
cluster). 
 
Subgenotype A1 isolates from co-infected individuals  were compared to  subgenotype A1 
isolates from Asian and African countries using a circular unrooted phylogenetic tree  (figure 
3.11). Three clusters could be discerned: containing strains from Central Africa (blue), one 
from southern eastern Africa (red) and an African/Asian cluster (“Asian”).  The details of 
these clusters are shown in figure 3.12A and 3.12B.  Fifteen isolates (HJH011B, HJ03B, 
S011A, S014A, S037A, S043A, S045A, S074A, S159A, S167A, S193A, S221A, S270A, 
S274A and S300A) clustered with the “Asian” subgenotype A1 (figure 3.12 A) cluster and 
the remainder of the isolates clustered with the African subgenotype A1 isolates (figure 
3.12B).  
 
Upon translation of the preS1/preS2/HBsAg and overlapping polymerase region, majority of 
the isolates from both African, Central African and “Asian” clusters  isolates showed distinct 
subgenotype A1 amino acids 54Q, 74V 86A and 91V in the pre-S1 region and 32L in the 
preS2 region (Kimbi et al., 2004). The following mutations distinguished the isolates in the 
“Asian” cluster from the southern eastern  African ones:  F25L and V88L in the preS1 region, 
R48T/K, A53V and L54P in the preS2 region. Eleven isolates from the “Asian” cluster had 
194A whereas the remaining four and all isolates from the southern eastern African clusters 
had  194V.   
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Figure 3.12A.  Phylogenetic tree comparing the South African subgenotype A1 in the 
“Asian” cluster to  Asian subgenotype A1 obtained from GenBank (designated by accession 
numbers), established using neighbor-joining, rooted using genotype D. Bootstrap statistical 
analysis was performed using 1 000 data set and the numbers on the nodes indicate the 
percentage of occurrences, ®PreS1 deletion , § preS2 deletions. * Spacer: 32Q 28L , 
#Spacer: 5L 6K,  Reverse transcriptase: ¥ 1D 
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 Figure 3.12B.  Phylogenetic tree comparing the South African subgenotype A1 in the 
southern eastern African cluster with African subgenotype A1 obtained from GeneBank 
(designated by accession numbers), established using neighbor-joining, rooted with genotype 
D. Bootstrap statistical analysis was performed using 1000 data set and the numbers on the 
nodes indicate the percentage of occurrences. *PreS1: 5T 6S, # Spacer: 94N, € Spacer 5S 6Q 
,
 ¥ 1D .  GenBank accession numbers: South Africa: AY233287, AY233279, AY233277, 
AY233276; Zimbabwe: HM535209, HM535221, HM535219, HM535208, HM535214, 
HM535205, HM535207, HM535194, HM535204, HM535215, HM535210, HM535206, 
HM535203, HM535201, HM535202, HM535121; Rwanda: FM199977, FM199981, 
FM19997, FM199976, FM199979, FM199980.  
 
80 
 
 
The southern eastern African cluster consisting of twenty four of isolates had distinct amino 
acid motifs  in the preS1/preS2/S region compared to the “Asian” cluster isolates (figures 
3.12A and 3.12B). The African isolates had greater variation in the preS1 compared to the 
“Asian” cluster (figures 3.12A and 3.12B). In the preS2 region, seven isolates had mutation 
L32H, while the remainder of the African isolates and “Asian” isolates had 32L. 
  
In the spacer region of the overlapping polymerase region, 13 of 15 isolates from the Asian 
cluster had 5I 6K and the remaining two had 5LK 6K. The strains in the southern eastern 
African cluster had different amino acid motifs  at position 5 and 6 for the five different 
clades:  two isolates (S107A and S148A)  had 5I 6Q, isolates S100A and S130A had 5S 6Q, 
5T 6K  together with 64A was found in three isolates (S110A, HJH12A A and HJH12B), 
seven isolates had 5S 6Q and 11 isolates had 5I 6 (figure 3.12B). 
 
Ten   of the 15 isolates had 24L together with P29 whilst the remaining 5 together with the 
African cluster isolates had 24Q and 29L. Ten “Asian” isolates had 59S while the remainder 
of the isolates including the isolates clustering with African cluster had 59P.  All “Asian” 
isolates had 68A compared to the southern eastern African isolates, which had 68P.  
 
The first amino acid of the reverse transcriptase domain of the overlapping polymerase was 
Asp in 10 of the 15 isolates instead of Glu . To check for validity of this mutation, 457 
sequences from the public databases were checked. This mutation was found in the 
following: all genotype G sequences, some Japanese subgenotype B1 (AB010291, 
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AB073854, AB010290, AB106884, AB073856, AB073849, AB0733838 and AB033554), 
Taiwanese subgenotype B2 (AY596105, AY167098, AY167093), Swedish   subgenotype B2 
isolate (A7121250) and one South African subgenotype A1 isolate (AY233290) (results not 
shown).  
3.6 Complete S region analysis 
3.6.1 Helen Joseph Hospital cohort 
 
Eight complete surface gene sequences of HBV isolated from the Helen Joseph Hospital 
cohort were analysed for mutations in the preS1, preS2, HBsAg regions and the polymerase 
region overlapping the HBsAg. In the preS1 region, F25L substitution mutation in the major 
pres1 antigenic epitope occurred in one isolate. The V90A occurred together with the S6A/P 
mutation in four isolates. Other mutations found in this region were S5L, I48V, H51Q, N40I 
and W77G. 
 
The preS2 region showed two deletion mutants previously described in HBV-HIV co-
infected patients (Audsley et al, 2010). Deletion mutants of 16 and 18 codons, one  from a 
baseline isolate and from a 6 month follow up isolate, respectively, were found. Subgenotype 
A1 determinant mutation L32H occurred in 3 isolates, twice with S47A mutation.  R48T/K 
occurred in two isolates from six months follow up patients only. The A53V mutation 
together with L54P was found in one isolate which had the 18 codon deletion mutation. 
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In the HBsAg region, four isolates showed the following mutations in the “a” determinant 
epitope (aa 99 to 150): I110M, K122R, T125M, M133T and F134I.  One baseline patient was 
infected with immune/vaccine escape mutant E164V. R24K, L49R, S155L, W156G, V194A 
and L209V mutations were also found in this region. The polymerase region overlapping the 
HBsAg region of the HBV genome showed no drug resistant mutations in isolates derived 
from either the baseline or 6 month follow up patients.  Substitution mutations rtQ125E and 
rtP109S occurred in 3 and 2 six months follow up isolates, respectively. The following 
mutations only occurred in a single isolate: rtH9Q + rtS119A+ rtV142N, rtY126H, rtI163T, 
rtL164W and rtE1D+ rtT128A 
3.6.2 The Shongwe Hospital Rural cohort 
 
The complete surface gene DNA sequences were obtained for 34 isolates.  Of the 34 
isolates 19 were HBsAg negative and 15 were HBsAg positive. (Figure 3.1).  Mutation 
analysis was done for all 34 isolates. The preS1, preS2, HBsAg and the overlapping 
polymerase   regions of the complete surface gene were analysed for the following 
clinically significant mutations: the deletion mutants,  vaccine/immune escape mutants, 
HBsAg “a” determinant mutations, HBV reactivation maker mutations, the overlapping 
polymerase drug resistant mutations and other significant  mutations.  These are 
summarized in table 3.1. 
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Table1 3.1. Mutations observed in the complete surface open reading and their statistical 
significance 
 Percentage of mutations in Statistical 
significance 
P value 
HBV 
region 
 
HBV 
mutation 
HBsAg  positive 
% (n = 19) 
 
HBsAg negative % 
(n= 15) 
Pr
eS
1 
 
S5T 
F25L 
I48V 
V88L 
L85M 
T90V 
P94T 
5.26 
55.55 
0 
55.55 
10.53 
36.84 
0 
6.67 
20.0 
46.67 
33.33 
0 
0 
20.0 
0.6952 
0.4941 
0.0008* 
0.4709 
0.3048 
0.0094* 
0.0760 
Pr
eS
2 
M1I 
A7T 
Q10R 
A11T 
F22L 
L32H 
R48K/T 
A53AV 
L54P/S 
10.53 
0 
10.53 
5.26 
21.05 
21.05 
36.84 
31.58 
31.58 
13.33 
26.67 
20.0 
6.67 
13.33 
6.67 
20.0 
20.0 
40.0 
0.4150 
0.0294* 
0.3836 
0.6952 
0.6952 
0.4525 
0.2507 
0.2466 
0.4394 
H
Bs
A
g 
V14G 
68 (M) 
Q101H/K 
M103L 
T115R 
S117N 
T118K 
Y100C 
P120T 
Q129R/H 
N131K 
D144E 
E164A/G 
V168A§ 
S174N§ 
I195M 
Y206H/C 
10.53 
5.26 
10.53 
5.26 
0 
0 
0 
5.26 
10.53 
5.26 
5.26 
5.26 
10.53 
10.53 
0 
0 
10.53 
0 
0 
0 
0 
6.67 
6.67 
6.67 
6.67 
0 
20.0 
13.33 
0 
13.33 
26.67 
20.0 
6.67 
0 
0.3048 
0.5588 
0.3048 
0.5588 
0.4412 
0.4412 
0.4412 
0.6952 
0.3048 
0.2158 
0.4150 
0.5588 
0.4150 
0.2197 
0.0760 
0.4545 
0.3048 
O
v
er
la
pp
in
g 
Po
ly
m
er
a
se
 rtE1D 
rtS105T 
rtH122N 
rtQ125E 
rtT128N/S 
rtL129M 
rtV173L 
rtL180M 
rtM204V 
rtV214A 
36.84 
10.53 
15.79 
21.05 
10.53 
0 
0 
0 
0 
5.26 
13.33 
13.33 
13.33 
6.67 
0 
6.67 
6.67 
6.67 
6.67 
0 
0.1242 
0.4150 
0.6164 
0.2507 
0.3048 
0.4412 
0.4412 
0.4412 
0.4412 
0.5588 
*Statistically significant§ 
 V168A together with S174N are reactivation markers and were found to be significantly      
higher in HBsAg-negative individuals (Henke‐Gendo et al., 2008). 
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In the preS1 region, the F25L amino acid mutation in the major preS1 binding occurred 
more frequently together with the V88L in three isolates (S70A, S193A and S270A) 
HBsAg negative isolates and in four HBsAg positive isolates (S014A, S016A  S159A, and 
S167A).  The T90V mutation occurred in 6 HBsAg positive isolates and 3 times with the 
V88L and none in the HBsAg negative isolates. Other mutations found in this region were   
I48V,   L85M,   P94T, S5T and one 30 nt deletion mutant at nucleotide position 2900- 
2929, commonly found in HCC patients (Kew et al., 2005).  
 
In the preS2 region, the R48T/K occurred in 12 isolates: 8 times together with the A53V 
and 4 times with L32H.  The Q10R mutation in the major preS2 antigenic epitope region 
was found together with the V53A and R48K frequently. PreS1/preS2 deletion mutants 
ranging from 11 to 33 codons previously associated with HIV co-infection (figure 3.13) 
(Audsley et al, 2010),  were found in  five isolates (S011A, S045A, S167A, S274A and 
S300A),  Other mutations in the preS2 region include the amino acid substitution 
mutations M1I which occurred together with  F22L, A7T, A11T and L54P/S ( table 3.1) 
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Figure 3. 13: Deletions observed in the PreS1/PreS2 region  of the HBV subgenotype 
A1 genome from HIV co-infected. Position 1 corresponds to the EcoRI cleavage site of 
HBV genome. 
 
The HBsAg region was analysed for vaccine/immune escape mutants.  Immune escape 
mutants P120T/A, Q129R and E164D/G were found in 7 isolates (figure 3.14). The 
following mutations were found in the vicinity of the ‘a’ determinant epitope of the 
HBsAg: Y100C, Q101H/K, M103L, T115R, S117n, T118K and N131K (figure 3.14).   
The HBV reactivation markers V168A + S174N   (Henke‐Gendo et al., 2008) were found 
in 23.81 % of the HBsAg negative and none in the HBsAg positive infections (figure 
3.15). The following mutations: D144E, E164D, I195M and Y206C also resulted in 
substitutions occurring in the overlapping polymerase region.  
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Figure 3.14: Graphical Representation of the mutations found on the HBsAg small 
envelope protein from the HBsAg-negatives. The red circles show the mutations found 
in the HBsAg “a” determinant epitope, yellow circles show the immune/vaccine escape 
mutants and the blue circles represents the HBV reactivation mutation markers. 
 
In the polymerase region, overlapping the HBsAg region, the following clinically 
significant drug resistant mutations were found in 3 isolates (S011A, S074A and S130A): 
rtL180M +rtM204V, rt V173L in HBsAg negative isolates and rtV214A in one HBsAg 
positive isolate (figure 3.15).  The substitution mutation on rtT128N/S occurred in 2 
isolates (S255A and S274A) as a result of the HBsAg overlapping mutation P120T. Other 
87 
 
mutations that were found in this region include rtS105T, which frequently occurred 
together with rtH122N, rtQ125E and rtL129M (table 3.1). 
 
 
 
Figure 3. 15. Clinically significant mutations of the complete surface open reading 
frame in the HBsAg positive and negative HBV infections.* statistically significant 
P<0.05.  PreS2 deletions depicted in figure 3.10; PreS2 start codon mutation: M1I; 
vaccine/immune escape mutants: P120T/A, Q129R and E164D/G; reactivation markers: 
V168A + S174N; Drug resistant mutations: rtV173L, rtL180M + rtM204V and rtV214A 
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Chapter 4: DISCUSSION 
 
HBV and HIV are both endemic in sub-Saharan Africa. Most of the research on HBV and 
HIV coinfection has been conducted in areas of low HBV endemicity, where a number of 
studies have found a significantly higher prevalence of HBV infection in HIV-positive 
individuals (Colin et al., 1999, Thio et al., 2002, Shire et al., 2007) . Therefore it is of great 
importance to study HBV-HIV co-infection in a South African context. It is known that HBV 
genotype A is predominant in South African HBV-mono infected population (Bowyer and 
Sim, 2000, Kimbi et al., 2004); however genotypes prevailing in a HBV/HIV co-infected 
population were previously unknown.   
 
Sequence variability is an important characteristic of the HBV because the viral polymerase 
(reverse transcriptase) lacks proofreading activity (Kramvis et al., 2005b). Host–virus 
interaction and selective pressure imposed internally by the immune system and externally by 
vaccination and antiviral treatment can also affect DNA sequence heterogeneity of the HBV 
genome (Kramvis and Kew, 2005).  Compared to areas of low endemicity, where HIV and 
HBV are most likely transmitted at the same time during sexual maturity, in South Africa, the 
main route of HBV transmission is by horizontal transmission, early in infancy.  
Transmission occurs generally before the age of 5 years and these children then become 
chronic carriers of HBV in adulthood (Kew, 1996). Therefore majority of the South African 
population are naturally protected by antibodies to HBV by the time they acquire HIV at the 
age of sexual maturity (Burnett et al., 2005). However, immunosuppression as a result of 
HIV infection has been shown to result in HBV infection and/or reactivation (Henke‐Gendo 
et al., 2008, Bloquel et al., 2010) , hence increasing HBV infection in HIV positive patients, 
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with previously resolved HBV infections. Reactivation of HBV infection can result in 
sequence heterogeneity leading to clinically significant mutations on the HBV genome 
(Henke‐Gendo et al., 2008),  which may have impact on liver disease progression.  
Moreover, the development of the mutations can be influenced by the HBV genotypes 
prevailing in a population.  Therefore this study was conducted to determine the HBV 
genotypes and to identify mutations occurring on the BCP/PC, the complete surface and the 
polymerase region overlapping the HBsAg, of HBV isolated from South African individuals 
with HIV infection. 
 
In order to determine the genotypes and to characterize the clinically significant mutations 
prevailing amongst the South African HIV positive population, blood serum samples were 
collected from HIV positive patients from both rural and urban hospitals. Following nucleic 
acid extraction, the partial surface gene, BCP/PC and the complete surface regions were 
amplified by PCR. The complete surface and the BCP/PC amplified products were sent for 
sequencing followed by bioinformatics analysis to determine the HBV genotypes and to 
identify mutations relative to the consensus sequences of the respective genotypes.    
 
4.1  HBV GENOTYPING METHODS 
 
Classical genotyping methods for HBV include PCR amplification and full genome 
sequencing followed by phylogenetic analysis. However, a number of other methods have 
been developed and used over the years. These include: restriction fragment length 
polymorphism (RFLP) (Lindh et al., 1997), PCR with specific primers for single genotypes, 
multiplex-PCR for many HBV genotypes (McIver et al., 2005), hybridisation technologies 
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and serology based approaches (Laperche et al., 2001, Usuda et al., 1999). In this study PCR- 
RFLP method and PCR-sequencing followed by phylogenetic analysis was employed. 
 
4.1.1 HBV genotyping by RFLP 
 
The RFLP method for genotyping HBV is based on the amplification of the partial S gene (nt 
256- 796), followed by restriction digestion of the amplicons. The partial surface region (nt 
256- 796) of 26 HBV isolates from HIV-infected individuals attending the  Helen Joseph 
hospital were successfully  amplified using nested PCR. HBV could only be visualized 
following nested PCR (figure 3.2), indicating relatively low viral loads. Using a RFLP 
genotyping assay (Lindh et al., 1997) , 13 of the partial surface region amplified products 
were restricted using the enzymes HinfI and  Tsp109. Six isolates from baseline samples and 
five from the six months follow up were found to belong to genotype A. One isolate 
(HJH20B) yielded a restriction pattern found to belong to genotype D ( figure 3.5)  which 
was further confirmed by direct sequencing of the complete surface gene.   
 
The RFLP method for HBV genotyping has an advantage over sequencing in that it does not 
require highly skilled personnel and may be more practical for large scale genotyping studies.  
This method can give an indication of the HBV genotypes prevailing in a population much 
quicker than sequencing and phylogenetic analysis because it does not require special 
sophisticated equipment. However, the RFLP restriction method for genotyping has 
shortcomings, which may result in poor results.  Low viral load/ low viral DNA 
concentrations may cause poor PCR amplification and restriction, single nucleotide mutations 
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resulting in change within the restriction sites may affect the digestion and the quality of 
genotyping.   
 
Since the method was described fourteen years ago, unusual patterns as a result of 
recombination, the presence of mixed genotypes and the increased number of genotypes and 
strains having been identified Thus this method may yield unreliable results, selecting only 
the most dominant genotype and missing mixed genotype populations.  The high cost of 
restriction enzymes may also limit the method as number different enzymes are required 
depending on the number of genotypes being studied in a specific region.  The method cannot 
differentiate subgenotypes or provide information about mutations in the HBV genome.  
Thereforethis  RFLP genotyping method was not used in the subsequent analyses of the HBV 
isolates from the Shongwe cohort.   
 
4.1.2 HBV genotyping by BCP/PC sequencing analysis 
 
Sequence and phylogenetic analysis using individual gene or gene sequence can also be 
employed for  genotyping of the HBV. The BCP/PC region is a small region of the HBV 
genome, which directs the transcription of the mRNAs which are translated into the precore 
HBeAg, the HBcAg and the polymerase (Gunther et al., 1996). Sequence analysis allows 
identification of specific nucleotides or nucleotide polymorphism distinct to certain genotype 
(Bartholomeusz and Schaefer, 2004), therefore the BCP/PC region  sequence analysis may 
allow to distinguish the different HBV genotype by looking at specific nucleotides between  
nt 1750 to 1900 (from the EcoR1 site). Compared to RFLP method, by using the BCP/PC 
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sequence analysis method, certain subgenotypes, such as subgenotype A1 and A2  may also 
be distinguished. 
 
The BCP/PC region was successfully amplified by a nested PCR, using standard DNA Taq 
polymerase, because it involved amplification of a relatively short fragment of 307 bp , which 
amplified even low viral loads.  Because of high sensitivity, samples with very high viral load 
showed a very strong DNA band on the agarose gel when viewed under UV light following a 
single PCR and following a second round of PCR yielded smeared bands. Therefore samples 
with very high viral loads were sent for sequencing following only a single PCR or diluted 
1:100 before running the second round PCR in order to get rid of all the non specificbanding 
and to obtain a clear specific single DNA band of 307 bp. Amplification of the BCP/PC 
region of HBV isolated from  the Shongwe Hospital samples needed additional optimisation. 
Because of  the sensitivity of the PCR, it was very difficult to avoid contamination and extra 
precautions were taken. Amplifications were repeated using one sample alternating with 
negative water control, dilution of the first round PCR products in 1:10, 1:50 and 1:100 to 
minimise carry over contamination and to reduce non-specificity.  A new pair of sterile 
gloves was worn before handling of each sample to avoid carryover contamination of 
negative samples.  To prevent cross contamination, different PCR hoods for first round and 
second round PCR were used. They were cleaned with bleach and 70 % ethanol and left 
under UV light for 20 to 30 min prior to each use. All the pipettes designated for each round 
of PCR were also cleaned with bleach and 70 % ethanol, and left under UV light prior to each 
use. The racks were soaked in bleach overnight and all the tubes used were autoclaved before 
use.  
 
93 
 
From a total of 51 Shongwe HBV isolates and 13  and Helen Joseph HBV isolates,  the 
BCP/PC region was successfully amplified and sent for sequencing,  A total of 49  isolates 
from Shongwe and 13 isolates from Helen Joseph generated DNA sequence data that were of 
good quality and could be properly assembled, aligned and analysed. Using the nucleotide 
region 1750 t0 1900 (from the EcoR1 site) in the BCP/PC region, sequence analysis was done 
and the subgenotypes were determined.   
 
The following loci in this region were analysed to identify genotype specific nucleotides: 
1809-1812, 1858, and 1888 (table 3.1).  From the Helen Joseph study, BCP/PC region of 13 
isolates were amplified,  sequenced and analysed. Eleven isolates had the TCAT Kozak 
sequence at nt 1809-1812, 1858C together with 1888A  (from the EcoR1 site) (figure 3.8), 
therefore  it could be deduced that belonged to subgenotype A1(Kramvis et al., 2008). The 
two other isolates (HJH11A and HJH 20B) had sequence characteristic of genotype D/E: 
Kozak sequence GCAC (1809-1812 from the EcoR1 site) and 1858T.  
 
Of the 49 BCP/PC DNA Shongwe Hospital sequences analysed, Thirty nine isolates were 
subgenotype A1 with the Kozak sequence TCAT at nt 1809-1812, T1858C and 1888A/G, 
which predominates in the HBV mono-infected population in South Africa. Three isolates 
had the Kozak sequence GCAC (1809-1812) with C1858T and 1888G, characteristics of 
genotype D or E.  Seven isolates with Kozak sequence GCAC, 1858C and 1888G were 
deduced to belong subgenotype A2 (Kramvis et al., 2008). 
 
Genotyping by BCP/PC sequence analysis advantages include easier PCR-amplification and 
PCR sensitivity due to the region’s small size. The analysis allows differentiation between 
subgenotypes A1 and A2, which cannot be done using the RFLP method. However, the 
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method also has restrictions in that it cannot differentiate genotypes D and E.  Although not 
predominant, both genotypes D and E may be found in South Africa and cannot be 
differentiated using the BCP/PC region. This is a limitation of genotyping using the BCP 
sequence analysis; however it can be overcame by phylogenetic analysis of the complete 
surface gene or full genome sequence. 
 
4.1.3  HBV genotyping by Complete S sequencing analysis 
 
The same procedure as the BCP/PC amplification was followed in amplification of the 
complete S region to avoid contamination. The complete surface gene PCR was less sensitive 
because of the longer length of the PCR product of 2 kb (figure 3.4).  Different temperatures 
and primer concentrations were tried using the normal Bioline Taq polymerase but yielded no 
PCR product. Therefore the Qiagen Hotstar Taq master mix was used, this master mix has 
optimised conditions and ready mixed buffers and to give high PCR specificity and reduced 
non-specificity. HBV isolates with relatively high HBV DNA viral loads were amplified 
successfully.  Those with much higher HBV viral loads had non-specific amplification and 
therefore required PCR gel purification prior to direct sequencing. 
 
Following PCR amplification, the complete surface region of 8 HBV isolates from Helen 
Joseph Hospital and 34 isolates from Shongwe Hospital were directly sequenced.   Following 
sequencing, the DNA sequences were analysed by phylogenetics and construction of 
phylogenetic tree against HBV genotypes A- H. The complete S analysis also allows to 
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determine HBV serological subtypes from translated HBsAg gene DNA sequences by 
looking at amino acids  122, 127 , 134, and 160 (Kramvis et al., 2008). 
A total of 37 complete surface DNA sequences were generated from the Shongwe Hospital 
study and eight isolated from the Helen Joseph Hospital.   Two isolates  (HJH12A and 
HJH12B)  from the Helen Joseph Hospital and eight isolates from Shongwe belonged to 
serological subtype  ayw2  with amino acid sequence 122R, 127P,  134F, and 160K  The 
remaining isolates  from Shongwe and Helen Joseph had amino acid characteristics (122K, 
127P , 134F, and 160K) depicting serological subtype adw2. Serological subtype adw2 is the 
most common serological subtype in South African genotype A/subgenotype A1 isolates 
(Kramvis et al., 2005b). 
 
Two isolates from Shongwe could not be accurately genotyped.  In the first case, the 
genotype deduced from the BCP/PC region was genotype A. Using the S region it was 
deduced to belong to genotypes D or A, because the chromatogram yielded a mixed pattern.  
In the second case, both the BCP/PC and S region amplifications yielded mixed 
chromatograms.  The discordant result between the BCP/PC and S region, as well as the 
mixed chromatograms can be either because the patient was infected with both genotypes A 
and D  or with a genotype D/A recombinant.  Genotype D/A recombinants have been shown 
to occur in South Africa (Owiredu et al).  The only way that this could be differentiated 
would be by carrying out full genome amplification to identify the recombinant and/or 
cloning to identify the mixed population.      
Upon construction of the phylogenetic tree  of all 42 complete subgenotype A1 S DNA 
sequences (from both Shongwe and Helen Joseph) (figure 3.10), only one isolate (S055A) 
from Shongwe was found to cluster with genotype D.  Phylogenetic comparison with 
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different subgenotypes of D (data not shown) this isolate was found to belong to  
subgenotype D3, previously found in HBV mono-infected individuals (Kimbi et al., 2004). 
Therefore as in the case of HBV mono-infection, the majority of HBV isolates from HIV co-
infected individuals belonged to subgenotype A1. All HBV isolates had amino acids in the 
BCP/PC and preS1/preS2/HBsAg region characteristic of subgenotype A1 (Kimbi et al., 
2004). Subgenotype A1 is the most prevalent subgenotype in South Africa. Genotyping by 
complete S analysis was found to be more accurate compared to the BCP/PC sequence 
analysis, since the S region amplified is longer than the BCP/PC and therefore more 
informative.  Sequencing of these two regions is generally sufficient to accurately genotype 
HBV isolates except in the case of mixed infections and/or recombinants, where full genome 
amplification and cloning would be necessary.   
 
4.1 .4  Phylogenetic analysis 
 
Phylogenetic analysis is a method to assess the relative and evolutionary relatedness of 
sequences to each other and control sequences (McCormack and Clewley, 2002). Genotyping 
by phylogenetic analysis  employs special algorithms and phylogenetic software packages to 
construct  evolutionary relatedness  tree using statistical analysis of DNA sequences of full 
genomes, or specific gene/ regions (Bartholomeusz and Schaefer, 2004).  
 
In this study, a circular un rooted phylogenetic tree was constructed for the 39 subgenotype 
A1 isolates from the Helen Joseph and the Shongwe cohort (figure 3.11) together with HBV 
subgenotype A1 isolates from different African and Asian countries. The  HBV subgenotype 
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A1 isolated from  HIV infected individuals clustered  together with African and Asian HBV 
isolates belonging to subgenotype A1 (figure 3.11), Even though these HBV subgenotype A1 
isolates were obtained from one small region in South Africa, these isolates showed high 
nucleotide diversity when compared to others from other geographical regions of the world. 
Phylogenetic analysis showed three different clusters: the Central African cluster (blue), the 
southern eastern African cluster and the African/Asian (“Asian”) cluster (figure 3.10). 
 
Isolates from the southern eastern African cluster formed different clades: subgenotype A1 
isolates from central eastern African countries (Malawi, Tanzania, Uganda and Central 
African Republic), Zimbabwe and South African (figure 3.11 Red). The isolates from the 
“Asian” cluster formed five major clades where the isolates from the HBV-HIV co-infected 
individuals clustered together with some South African HBV mono-infected subgenotype A1 
isolates, the United Arab Emirates clade, South Eastern Asia (Japan, Philippines and India). 
Somalian isolates clustered in this cluster and formed clades with HBV subgenotype A1 from 
Bangladesh, India, Japan, Nepal and Philippines (figure 3.11 Green), whilst the Rwandan 
isolates formed an outlier slightly apart from the others (figure 3.11 Blue). 
 
Phylogenetic analysis does not only give genotype specific information but may also indicate 
relatedness of the transmission patterns, human behavioural patterns, and   historical human 
migration patterns between the countries represented by the clusters or clades (McCormack 
and Clewley, 2002). It also gives evolutionary information and statistical reliability. 
However, because of  the complexity of the method’s expensive algorithms required to do the 
analysis, specially trained personnel are required in interpreting the results and it may be time 
consuming (Bartholomeusz and Schaefer, 2004). 
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In summary, by employing the HBV genotyping methods discussed above, subgenotype A1 
was found to be most prevalent in both rural and urban South African HIV-infected 
individuals.  This higher prevalence same as in HBV mono-infections although the ratio of 
genotype A to non-A is slightly higher in the HBV/HIV co-infected individuals.  The 
previous study was carried out in 2004 (Kimbi et al) making direct comparison unfeasible.  
However, others have shown a predominance of genotype A in HIV infected individuals 
(Quarleri et al., 2007, Audsley et al., 2010)  
 
The HBV isolates were found in both African and “Asian” clusters intimating a high diversity 
in the strains circulating in both the urban and rural cohorts.  This high diversity may be 
indicative of the high mobility of populations to and from different northern countries in 
Africa to South Africa.   Johannesburg being an urban centre attracts a lot of immigrants 
(Collinson et al., 2007).  Moreover, Shongwe is close to the borders with Swaziland, 
Zimbabwe and Mozambique. Hence high levels of migration from these surrounding 
countries may lead to higher risk of sexually transmitted infections including HBV and 
further increased genetic variability of HBV  (Collinson et al., 2007). 
 
4.2 BCP/PC mutation analysis. 
 
The BCP and PC/C regions of HBV encode for HBeAg.  The BCP, which covers the distal X 
region and the proximal pre-core region, directs the transcription of pre-core mRNA, which is 
translated into the pre-core/core fusion protein that is the precursor of HBeAg. This region 
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possesses two start codons, HBeAg precursor protein,  which is synthesized by translation 
from the first start codon and the second start codon translates into the of the core protein 
(HBcAg), when it is translated from the pgRNA (Byung Chul et al., 2003).  A number of 
mutations that abolish and/or decrease HBeAg expression have previously been described 
(Kramvis et al., 1997b, Kramvis et al., 1998a, Lim and Ton, 2006). In this study   the BCP/PC 
region of 49 HBV isolates from Shongwe and 13 from Helen Joseph Hospital were analysed. 
 
In the Shongwe Hospital cohort, only five HBV isolates were HBeAg-positive and the 
remainder were HBeAg-negative.   For the Helen Joseph Hospital cohort,  HBeAg status was 
not determined because of the depletion of the serum. Variations or mutations that are 
characteristic  of subgenotype A1 have been described, that can account for  the HBeAg 
negativity.  These mutations can affect expression of HBeAg   at the transcriptional, 
translational and post-translational levels (Kramvis and Kew, 2007a, Chen et al., 2008a).  
 
The BCP/PC region was analysed for mutations in region 1750 - 1900 (from the EcoRIsite) 
as described in Kramvis et al, 2008 In five Shongwe isolates (S016A, S027A, S032A, S042A 
and S167A),  the classic precore G1896A mutation was detected (Carman, 1997)  This 
mutation completely abolishes HBeAg expression and it occurred with other mutation.  The 
G1896A converts the codon TGG for tryptophan to a stop codon leading to the truncation of 
the HBeAg precursor  (Carman et al., 1989).  The G1896A mutation occurred together with 
the C1858T in four of the five isolates (table 3.1, Appendix D), because in genotype A 
isolates  the G1896A disrupts the G-C Watson Crick bond, destabilizing  ε and compromising  
viral replication (Lok et al., 1994). Thus the C1858T mutation is frequently associated with 
the 1896 stop codon mutation (Kramvis et al., 2005b, Revill et al., 2010). 
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Another important  mutation in the precore/core region is the first initiation codon mutation at 
region 1814-1816 (non-ATG).  This was found in nine Shongwe isolates (table 3.1) and in 
none of the Helen Joseph isolates. This mutation alters the start codon preventing initiation of 
HBeAg translation (Laras et al., 1998). One of the eight isolates (S274A) with the initiation 
codon mutation was HBeAg positive (table 3.1), the initiation codon mutation completely 
abolishes HBeAg expression therefore; the HBeAg positivity may be explained by the 
presence of a mixed HBV infection, with the minor population providing a wild-type 
initiation codon.  
 
In the BCP region, four isolates (HJH01A, HJH03A, HJH10A and HJH01B) from the Helen 
Joseph cohort (figure 3.8) and eight HBV isolates (table 3.1) from Shongwe had the A1762T 
G1764A mutations.  These mutations are known to down regulate HBeAg expression and 
have been shown to increase viral replication and to be closely related to progression of 
chronic liver disease (Baptista et al., 1999, Hiroshi et al., 2002, Song et al., 2005, Tong et al., 
2005, Buckwold et al., 1996, Baumert et al., 2007). Isolate HJH10A from Helen Joseph also 
had the T1753C mutation together with the A1762T G1764A was found in one Helen Joseph 
isolate (HJH10A) and five (S061A, S148A, S184A, S221A and S264A) Shongwe isolates. 
This combination of  mutations have been described as markers for HCC (Yeh et al., 2010, 
Chen and Oon, 2000, Zhang et al., 2010).  
 
Ten DNA sequences from Helen Joseph had the TCAT Kozak sequence at nt 1809-1812, 
which is found in all South African  subgenotype A1, one isolate had TCTT instead of TCAT 
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and the remaining 2 had GCAC, which is found in subgenotypes other than A1. Thirty nine 
isolates had the TCAT and 10 had GCAC at position 1809-1812. Three nucleotide 
substitutions within this region were detected in seven of the 39 subgenotype A1 and two of 
subgenotype A2 isolates from Shongwe.  These triple  mutations may completely switch off 
HBeAg expression (Ahn et al., 2003). The point mutations around  the Kozak sequence are 
generally  found in subgenotype A1 and not in other genotypes, These mutations reduces a 
HBeAg translation by the leaky scanning mechanism (Kozak, 1999). This a process by which 
the 40s ribosomal unit locates the mRNA initiation codon,  which is  key step in translation 
and is  required for the expression of almost all eukaryotic genes (Berthelot et al., 2004, 
Kozak, 1999). In a South African population, the Kozak sequence mutation in the 1809-1812 
region was shown to occur in about 80% of South African HBV subgenotype A1 isolates 
(Baptista et al., 1999).    This set of mutations is a characteristic of subgenotype A1 (Kimbi et 
al., 2004), decreasing HBeAg at the translational level (Kramvis and Kew, 2007c, Ahn et al., 
2003).  This is a possible alternative mechanism of early  HBeAg seroconversion in patients 
infected with subgenotypes A1., . 
 
When comparing the mutations with the HBsAg status, the G1862T mutation occurred in 
23% of the HBsAg-negative patients but in none of the HBsAg-positive patients (p<0.05) 
(figure 3.10.). This mutation which interferes, with the post-translational modification of the 
HBeAg-precursor, together with the Kozak sequence mutation (1809-1812) and the A1762T 
G1764A may completely abolish HBeAg expression.  This mutation, in combination with 
two of these mutations,  could thus account for  the HBeAg negativity of seven isolates in the 
present study. 
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The 1888 region had a single nucleotide substitution mutation in four of the Helen Joseph 
isolates and in 20 Shongwe isolates.   The G1899A mutation occurred in 3 cases from 
Shongwe and in  none of the Helen Joseph isolates. The 1888 G to A mutation introduces an 
out-of-frame AUG start codon, 13 nucleotides upstream of the core AUG start codon and a 
minicistron that can potentially be translated into seven amino acids: ‘Met-Ala- Leu-Gly-His-
Gly-His’. Therefore, the newly introduced start codon at 1888 may have an important role in 
the regulation of the translational efficiency of a downstream start codon (Kimbi et al., 2004).  
 
4.3 COMPLETE S REGION ANALYSIS 
 
Phylogenetic analyses of the complete S region was used  to compare the subgenotype A1 
isolates from Helen Joseph and Shongwe Hospitals,  against subgenotype A1 HBV isolates 
from  Asian and African countries. The sequences separated into two distinct clusters: the 
African (Congo, Rwanda, South Africa and Zimbabwe) and the “Asian” cluster (Bangladesh, 
India, Philippines, Japan, Nepal, Somalia, United Arab Emirates and South Africa) (figures 
3.12A and 3.12B).  The isolates from the African cluster showed a lot of variation compared 
to the “Asian” cluster, which comprised of mostly Asian subgenotype A1 isolates, some 
South African and Somalian isolates.  The latter isolates did not show much variation in the 
preS1/preS2/HBsAg and spacer regions (summarised in figures 3.12A and 3.12B).   This 
concurs with the hypothesis that this subgenotype has been endemic in the African population 
for a long period of time (Kramvis and Kew, 2007c). 
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The complete S region has fundamental biological importance. It encodes for three distinct, 
related proteins LHBs, MHBs and SHBs, which share the same carboxyl terminal LHBs and 
MHBs encoded by the   preS/S region of the HBV, have been found to mediate attachment of 
the virus to the host receptors (Neurath et al., 1986, Huy et al., 2003). Moreover, B-cell and 
T-cell epitopes are also located on the portion of the proteins coded for by the preS region.   
The HBsAg contains a cysteine rich “a” determinant,  which is the major target of 
neutralising antibodies against HBV  (Jilg et al., 1984). Of all the variations known to occur 
on the HBV genome, the mutations within the surface are some of the most relevant 
clinically.  They are known to affect immunogenicity of the HBsAg, determined more 
specifically by the cysteine-rich ‘a’ determinant. This is the region  in which  a cluster of 
epitopes targeted by neutralizing antibodies against HBV are raised , any alterations in this 
region are important because they allow the virus to avoid the neutralizing effect of the host’s 
immunoglobulins (HBIg) (Jilg et al., 1984). Therefore, changes in the surface protein affect 
the antigenicity and immunogenicity of HBsAg, leading to immune escape and diagnostic 
difficulties, giving false negative results (Carman, 1997, Hsu et al., 1999). Mutations in the 
surface antigen may occur naturally as a result of the replication of HBV or may be induced 
by external factors such as vaccination and drugs against HBV. These mutants are able to 
infect vaccinated and unvaccinated individuals. Therefore in the context of HBV/HIV co-
infection, and especially in the presence of high HBsAg-negativity seen in this patient 
population, it was of great importance that these mutations be defined. 
 
In this study, eight isolates from Helen Joseph and 34 isolates from Shongwe Hospital were 
analysed. HBsAg status for Helen Joseph status could not be determined because of  serum 
depletion. From the Shongwe study, 15 isolates were HBsAg-negative and 19 isolates were 
HBsAg positive. The three regions: preS1, preS2 and the HBsAg regions as well the 
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polymerase region overlapping the HBsAg region were analysed for mutations including 
immune/vaccine escape mutants, ‘a’ determinant mutations, drug resistant mutations and 
mutations that may be unique to HBV-HIV co-infected with subgenotype A1 HBV isolates.  
Furthermore, sequences were analyzed in an attempt to explain the HBsAg negativity in these 
patients (summarised in table 3.1).  
 
Five isolates from the “Asian” cluster had preS deletion mutants:  one Helen Joseph isolate 
and  four HBsAg-positive Shongwe isolates had preS2 deletion mutants: (figure 3.12A).   
Deletion mutants in the preS region have been previously found to occur more frequently in 
HIV-coinfected patients (Audsley et al., 2010)  and in  HCC patients (Raimondo et al., 1991, 
Kew et al., 2005). Deletion mutants in the preS region have  been reported to cause 
overproduction and accumulation of LHBs protein in the endoplasmic reticulum (ER), which 
causes significant ER stress that may induce DNA damage and genomic instability and hence 
play a possible role in hepatocarcinogenesis (Hsieh et al., 2004, Chen et al., 2006). A higher 
oncogenic potential of pre-S2 deletions has been found compared with that of pre-S1 deletion 
mutants (Yeung et al., 2011). The preS mutants may contribute to   viral oncogenesis by  
transcriptional activation of the viral promoter elements (Hildt et al., 1996). 
 
All sequences from both Helen Joseph and Shongwe Hospital had the 54Q and 91V, which 
have been shown to be a characteristic of subgenotype A1 in the preS1 region (Kimbi et al., 
2004, Norder et al., 1996). Pres1 residues 21-96 contain the virus neutralising epitope and a 
hepatocellular binding site and the preS2 residues 1-11 and 21-47 are have been shown to 
mediate HBV attachment to the hepatocytes (Kim et al., 1997), therefore mutations in these 
regions may lead to  conformational changes on the LHBs and MHBs,  which may result in 
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HBsAg negativity. PreS1 mutations within the neutralising epitope and hepatocellular 
binding sites were detected: S5L, S6A/P, F25L, I48V, N40I (summarised in table 3.1) and in 
addition to this F25L, L54P/S L85M, V88L, T90V and P94T were found in isolates from 
Shongwe.   The preS2 start codon mutation M1I was found in a statistically higher proportion 
of HBV from HBsAg-negative individuals compared to isolates from HBsAg-positive 
individuals.  In the preS2 region, L32H substitution was found in 3 of the 8 isolates from 
Helen Joseph and in 8 of 34 isolates from Shongwe.  This mutation is a unique subgenotype 
A1 determinant  (Kimbi et al., 2004). R10Q was observed in 5 isolates from Shongwe.  This 
mutation is in the major preS2 antigenic region known to carry numerous B cell, T-helper cell 
and cytotoxic T-lymphocyte epitopes (Paulij et al., 1999). Therefore this mutation may 
reduce the binding ability of the antibodies to the epitope and interfere with their neutralising 
effect. 
 
All the participants of the study were over the age of 18.  In South Africa vaccination against 
HBV was introduced into the Expanded Programme for Immunization (EPI) in 1995, 
therefore it is unlikely that any of the participants had received this vaccine.  However, HBV 
immune/vaccine escape mutants in the HBsAg region were detected in three isolates 
(HJH01A, HJH12A and HJH12B) from Helen Joseph and 11 isolates from Shongwe. One 
Helen Joseph isolate (HJH07A) had escape mutant E164V. This mutation may interfere with 
recognition of HBsAg by antibodies, showing reduced binding to anti-HBs antibodies and 
has the potential of vaccine/immune escape (Torresi, 2002). The K122R mutation was 
detected in 2/8 isolates (HJH12A and HJH12B) from Helen Joseph.  The amino acid at this 
position is used to determine the d/y specificities in the serological subtype and therefore this 
mutation results in the conversion of the adw subtype to ayw (Kramvis et al., 2008). The 
serological subtype ayw occurs in the minority of subgenotype A1 isolates (Kramvis et al, 
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2008) and is mainly confined to isolates mainly originating in Malawi (Sugauchi et al., 
2003). Serological subtype ayw is mostly found in genotype D and have been isolated from 
genotype A isolates from South Africa (Bowyer et al., 1997a), Zimbabwe (Chirara and 
Chetsanga, 1994) and Cameroon (Norder et al., 1992b) 
 
From the Shongwe Hospital study, five out of 15 HBsAg positive isolates and 6 out of 19 
HBsAg negative isolates (figure 3.15) had immune/vaccine escape mutants. Six isolates had 
the vaccine escape mutant F129R and one with E164G/R.  F120T occurred together with the 
E164G/R in two isolates. The F120T is a vaccine escape mutant which produces changes in 
the rtT128N in the polymerase protein and have been  found to partially restore the in vitro 
replication phenotype of LMV resistant HBV (Torresi et al., 2002). 
 
The following mutations in the ‘a’ determinant were found in different combinations in 8 
isolates: C100Y, Q101H, M103L, T115R, S117N, T118K and N131K (figure 3.14). The 
HBsAg, which is the region containing the ‘a’ determinant (nt 99-150) is very significant for 
anti-HBIg binding and is targeted by antibodies used in standard HBV tests. Any alteration in 
this region may result in clinically significant mutations, which include, the vaccine/immune 
escape mutants, drug induced mutants and the ‘a’ determinant mutants. The mutations may 
result in false positive tests for HBsAg, which is used as one of the standard test to check for 
HBV.  Therefore these mutations may be the reason for the HBsAg-negativity seen the 
patients infected with HBV isolates carrying these mutations.   
 
107 
 
 Of great interest was the presence of previously identified reactivation markers 
(Henke‐Gendo et al., 2008).   The reactivation mutation markers V168A together with S174N 
occurred in 5/19 of the HBsAg negative patients and in none of the HBsAg positive patients 
(P<0.05). These have previously been shown to occur in patients who resolved HBV but in 
whom the infection was reactivated as a result of  HIV immune suppression (Henke‐Gendo et 
al., 2008). 
 
The polymerase region is one of the most conserved regions since the polymerase plays a 
major role in the replication cycle of the virus. However, long term therapy with nucleotide(s) 
analogues can lead to selection of drug-resistant mutants, which over time may become 
dominant quasispecies. Because the polymerase region overlaps the HBsAg of the HBV 
genome, the drug-resistant mutations may also affect the antigenicity of the HBsAg and vice 
versa. Therefore these drug resistant mutants, selected during therapy, have the potential to 
become in addition immune/vaccine escape mutants (Sheldon et al., 2007, Torresi, 2002).  
 
The overlapping polymerase region of HBV isolated from patients attending the Helen 
Joseph Hospital showed no drug resistant mutations. A few substitutions in the polymerase 
region were detected in HBV isolates from Shongwe, including,  rtQ125E in 3 isolates and 
rtF109S, these mutations have not been previously described and their significance is 
unknown.  Three Shongwe HBV isolates had drug resistant mutations. The rtV214A was 
detected in one HBsAg positive isolate and had the corresponding mutation Y206C in the 
HBsAg region. Lamivudine associated drug resistant mutants rtL180M together with 
rtM204V were detected in one HBsAg-negative isolate and results in the corresponding 
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HBsAg mutation, I195M. The I195M has been found to restore replication efficiency lost by 
the rtM204V in the polymerase region (Szomor et al., 2008, Yeh et al., 2000).  
 
Another lamivudine-associated mutation, rtV173L occurred alone in one HBsAg negative 
isolate with the corresponding E164P mutation in the overlapping HBsAg region. The 
rtV173L together with rtL180M + rtM204V are lamivudine selected mutations which may 
cause vaccine escape mutants which may results in impaired secretion of the HBsAg 
(Sheldon et al., 2006).One stop codon mutation was detected at position sC69STOP of the 
HBsAg region in an isolate from a HBsAg-positive individual, who also had HBV with the 
rtV214A drug resistant mutation. Other lamivudine resistant mutations  
(rtA181T/sW172STOP, rtV191I/sW182STOP and rtV207I/sW199STOP) have been shown 
to cause premature stop codons in the HBsAg region, which may result in impairment of 
HBsAg secretion, resulting in HBsAg negativity (Sheldon and Soriano, 2008). 
  
An unusual start codon mutation, rtE1D, was seen in eight isolates, which grouped in the 
“Asian” cluster following phylogenetic analysis. This mutation occurred together with 
rtS105T + rtH122N in 7 isolates and with rtQ125E in three isolates. After comparison of 
these isolates with 457 sequences from GenBank, the rtE1D mutation was found in isolates 
from genotype B and G from Asian countries. Glutamic acid (E) and aspartic acid (D) have 
similar chemical structures and properties; therefore this mutation is not expected to 
introduce a big functional change to the reverse transcriptase polymerase and the isolates are 
probably replicative. 
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All the mutations described occurred in genotype A.  This is in agreement previous studies 
that demonstrated that compared to other genotypes,  genotype A in HBV-HIV co-infected 
patients is more prone to drug associated mutations, immune/vaccine escape mutants, preS 
mutants associated with immune suppression and HCC (Thio et al., 2002, Audsley et al., 
2010, Iacomi et al., 2009);  and  BCP mutations, which may result in HBeAg-negativity (Ahn 
et al., 2003, Kramvis et al., 1997b, Baptista et al., 1999, Laras et al., 1998). Considering that 
lamivudine is extensively used in South Africa as part of the ART regimen, the presence of 
these mutations, prior to the initiation of ART in HBV/HIV-infected individuals, is a 
significant observation, which  needs to be investigated further.
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Chapter 5:  Conclusion 
 
In conclusion, the study showed subgenotype A1 predominates in HBV-HIV co-infected 
individuals from both urban and rural South Africa.  Subgenotype A1 HBV isolates have 
mutations that can affect HBeAg-expression at the transcriptional, translational and post-
translational level (Kramvis and Kew, 1999) and these mutations can account for the HBeAg-
negativity seen in the majority of HBV-HIV infected individuals from Shongwe.  Although 
there were no significant differences between the mutations occurring in HBV from  HBsAg 
positive and negative individuals, preS region mutations and deletions and  “a” determinant, 
immune/vaccine escape mutants may account for HBsAg negativity seen in some patients.     
Moreover, the standard commercial tests being used currently in South Africa in the health 
services will be unable able to detect these HBsAg mutants and HBV infection will remain 
undetected.  Nucleic acid detection of HBV can provide an alternative testing method for 
HBV because it can detect HBV DNA in the presence or absence of HBsAg in the serum.   
Deletion mutants have previously been shown to occur in HBV from HCC patients were 
detected in the present study.  These could be a risk factor for  the development of HCC in 
HIV patients, whose lifespan is being increased following the introduction of HAART. Thus 
more studies are necessary to functionally characterize these deletion mutants.  The presence 
of drug resistant mutations in the polymerase region, prior to the initiation of HAART, which 
to date has contained Lamivudine, has important implications and repercussions.  These 
mutants are replicative, can be transmitted and can cause liver disease including chronic 
hepatitis and eventually HCC.  This study has provided important information on the 
molecular characteristics of HBV in HIV infected individuals prior to the initiation of ART, 
which may have important clinical relevance. 
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APPENDIX C: SOLUTIONS, CHEMICALS AND REAGENTS 
 
10X TBE Buffer 
 
108 g Tris base 
55 g Boric acid 
9.3 g EDTA 
Make up to 1 L volume with additional distilled water and autoclave 
 
1X TBE Buffer 
 
1 ml of 10X TBE   
Fill up with distilled water to final volume of 1 L 
 
1% agarose 
 
1 g agarose 
100 ml 1X TBE 
Microwave until agarose as completely dissolved,  
Add Ethidium Bromide and pour on the gel casting tray with a comb and allow to set  
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APENDIX D: BCP/PC MUTATION ANALYSIS.  
 
  HBeAg positie 
   HBV active infection 
  HBV occult infection 
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